Document:

EX-4.2

 Exhibit 4.2 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 20, 2021, by and among Affinia
Therapeutics Inc. (f/k/a TDTx Inc.), a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. 

RECITALS: 
 A.
Certain of the Investors (the “Existing Investors”) hold shares of Series A Preferred Stock (as defined below) and Series A-1 Preferred Stock (as defined below) and possess registration
rights, information rights, rights of first offer, and other rights pursuant to that certain Investors’ Rights Agreement dated as of March 12, 2020, by and among the Company and such Existing Investors (the “Prior
Agreement”); 
 B. The Existing Investors are holders of at least a majority of the Registrable Securities (as defined in the
Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; 

C. The Company and certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even date
herewith (the “Purchase Agreement”), under which the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such Investors, Existing Investors holding at least a
majority of the Registrable Securities, and the Company. 
 D. In order to induce the Company to enter into the Purchase Agreement and
to induce the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common
Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement. 

The Existing Investors hereby agree that the Prior Agreement shall be amended and restated, and the parties to this Agreement further agree as
follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including, without limitation, any general partner, limited partner, member, manager, managing member, employee, officer, director or trustee of such Person, or any other trust for the
benefit of any of the foregoing or any Affiliate of the foregoing, or any venture capital fund or registered investment company or other investment fund now or hereafter existing that is controlled by one or more general partners, managing members
or investment advisors of, or shares the same management company or investment adviser with, such Person. For purposes of this definition, the term “control” when used with respect to any Person shall mean the power to direct the
management or policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise, and the terms “controlling” and “controlled” shall have the meanings correlative to the
foregoing. 

 1.2 “Atlas” means Atlas Venture Fund XI, L.P. 

1.3 “Board of Directors” means the board of directors of the Company. 

1.4 “Certificate of Incorporation” means the Company’s Second Amended and Restated Certificate of Incorporation,
as amended and/or restated from time to time. 
 1.5 “Common Stock” means shares of the Company’s common stock,
par value $0.0001 per share. 
 1.6 “Competitor” means a Person engaged, directly or indirectly (including through
any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in a business that is a competitor of the Company, but shall not include (a) any financial investment
firm or collective investment vehicle that, together with its Affiliates, holds less than 20% of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of
any Competitor, or (b) EcoR1, Farallon, Atlas, F-Prime, NEA, Lonza, MEEI, RA Capital, TCG, Perceptive, or any of their respective Affiliates. 

1.7 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject
under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement
of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act,
the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.8 “Deemed Liquidation Event” means a Deemed Liquidation Event as defined in the Certificate of Incorporation. 

1.9 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in
each case, directly or indirectly), Common Stock, including options and warrants. 
 1.10 “EcoR1” means EcoR1 Capital
Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P., together with their Affiliates. 
 1.11
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.12 “Excluded Registration” means (i) a registration relating to the sale or grant of securities to employees of
the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the
same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of
debt securities that are also being registered. 

  
 2. 

 1.13 “Farallon” means Zone III Healthcare Holdings, LLC, together
with its Affiliates. 
 1.14 “FOIA Party” means a Person (other than MEEI) that, in the reasonable determination of
the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552
(“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.15 “Form S-1” means such form under the Securities Act as in effect on
the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.16 “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward
incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 1.17 “F-Prime” means F-Prime Capital Partners Life Sciences Fund VI LP. 

1.18 “GAAP” means generally accepted accounting principles in the United States as in effect from time to time. 

1.19 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.20 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, domestic
partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.21 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.22 “IPO” means the Company’s first underwritten public offering of its Common Stock under the
Securities Act. 
 1.23 “Lonza” means Lonza Houston, Inc. 

1.24 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds,
and so long as it holds, at least 1,300,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.25 “MEEI” means Massachusetts Eye & Ear Infirmary. 

1.26 “NEA” means New Enterprise Associates 17, L.P. 

1.27 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as
well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

  
 3. 

 1.28 “Partners” means Partners Innovation Fund, LLC. 

1.29 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other
entity. 
 1.30 “Preferred Directors” means, collectively, the Series A Directors and the Series B Director. 

1.31 “Preferred Stock” means, collectively, shares of the Series A Preferred and Series B Preferred Stock. 

1.32 “Qualified SPAC Transaction” means a Qualified SPAC Transaction as defined in the Certificate of Incorporation.

 1.33 “RA Capital” means collectively, RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital
Management, L.P. and their Affiliates. 
 1.34 “Registrable Securities” means (i) the Common Stock issuable or
issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company held by the Investors, in each case
acquired by the Investors after the date hereof; (iii) Common Stock held by Lonza on the date hereof; (iv) Common Stock held by MEEI on the date hereof; and (iv) any Common Stock issued as (or issuable upon the conversion or exercise
of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i), (ii), (iii) or (iv) above, for so long as such shares
are considered Registrable Securities; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for
purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.35 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.36 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in
Section 2.12(b) hereof. 
 1.37 “SEC” means the Securities and Exchange Commission. 

1.38 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.39 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.40 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.41 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer
taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

  
 4. 

 1.42 “Series A Director” means any director of the Company that the
holders of record of the Series A Preferred are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 

1.43 “Series A Preferred” means, collectively, shares of the Series A Preferred Stock and the Series A-1 Preferred Stock. 
 1.44 “Series A Preferred Stock” means shares of the
Company’s Series A Preferred Stock, par value $0.0001 per share. 
 1.45 “Series
A-1 Preferred Stock” means shares of the Company’s Series A-1 Preferred Stock, par value $0.0001 per share. 

1.46 “Series B Director” means any director of the Company that the holders of record of the Series B Preferred Stock
are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 
 1.47 “Series B
Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 
 1.48
“SPAC Transaction” means a transaction or series of related transactions in which the Company’s outstanding shares of capital stock are exchanged for or otherwise converted into securities that are publicly listed on a
securities exchange (the “Public Shares”) through a merger, acquisition, business combination, or similar transaction with a special purpose acquisition company or its subsidiary or parent (a “SPAC”). 

1.49 “TCG” means TCG Crossover Fund I, L.P., together with its Affiliates. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) three years after the
date of this Agreement or (ii) 180 days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of 50% of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement covering the registration of Registrable Securities with an anticipated aggregate offering price, net of Selling Expenses, of at least $20 million, then the Company shall
(x) within 10 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within 60 days after the
date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered
and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case,
subject to the limitations of Sections 2.1(c) and 2.3. 

  
 5. 

 (b) Form S-3 Demand. If at any time
when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $2.5 million, then the Company
shall (i) within 10 days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is given by
the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by
notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration
statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate
reorganization, or other similar transaction involving the Company, (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential, or (iii) render the Company
unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be
tolled correspondingly, for a period of not more than 120 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any 12 month period; and provided
further that the Company shall not register any securities for its own account or that of any other stockholder during such 120 day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a)(i)
during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration, provided that the Company is
actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating
Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to
effect, or to take any action to effect, any registration pursuant to Section 2.1(b)(i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 90 days after the
effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has
effected two registrations pursuant to Section 2.1(b) within the 12 month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such
time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one
demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d); provided, that if such withdrawal is during a
period the Company has deferred taking action pursuant to Section 2.1(c), then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this
Section 2.1(d). 

  
 6. 

 2.2 Company Registration. If the Company proposes to register (including, for
this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of
Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this
Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne
by the Company in accordance with Section 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request
by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting; provided, however, that no Holder (or any of their assignees) shall be
required to make any representations, warranties or indemnities except as they relate to such Holder’s ownership of shares and authority to enter into the underwriting agreement and to such Holder’s intended method of distribution, and the
liability of such Holder shall be several and not joint, and limited to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s)
advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be
underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders
to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters
may round the number of shares allocated to any Holder to the nearest 100 shares. 
 (b) In connection with any offering involving an
underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the
underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of
securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is
compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included
in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such
selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no
event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering or (ii) the number of
Registrable Securities included in the offering be reduced below 25% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the
determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired
members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of
Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

  
 7. 

 (c) For purposes of Section 2.1, a registration shall not be counted as
“effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than 50% of the total number of Registrable Securities that Holders have requested to be included in such registration
statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this Section 2 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with
the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable best efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the
Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however,
that such 120 day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such
registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC
rules, such one hundred twenty (120) day period shall be extended for up to 90 days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such
other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 8. 

 (e) in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f) use its
commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which
similar securities issued by the Company are then listed; 
 (g) provide a transfer agent and registrar for all Registrable
Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition
pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the
Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has
been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j)
after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6 Expenses
of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and
accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the
Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders
of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the
Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be then the Holders shall not be required to pay any of such expenses and shall not forfeit
their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of
Registrable Securities registered on their behalf. 

  
 9. 

 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members,
officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter
within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby
in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to
amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they
arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in
connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Section 2.8(b) and
2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

  
 10. 

 (c) Promptly after receipt by an indemnified party under this Section 2.8 of
notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any
other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may
be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a
reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s
ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction
and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses,
claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified
party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or
by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required
to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to
this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the
case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

  
 11. 

 2.9 Reports Under Exchange Act. With a view to making available to the Holders
the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information,
as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent
accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time
after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the
prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) provide to such holder or
prospective holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the
registration and offering all shares of Registrable Securities that they wish to so include or (ii) allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or
prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; provided that this
limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Section 6.9. 

2.11 “Market Stand-off” Agreement. 

(a) Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period
commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company or the managing underwriter, as applicable (such period not to exceed 180 days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to
purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for the IPO, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of
this Section 2.11(a) shall apply only to the IPO and shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement or the transfer of any shares to any trust for the direct or indirect benefit of the Holder
or the Immediate Family Member of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for
value, and shall be applicable to the Holders only if all officers, directors, and stockholders individually owning more than 1% of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding
Preferred Stock), are subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11(a) and shall have the right, power
and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with any such registration that are consistent
with this Section 2.11(a) or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company
stockholders that are subject to such agreements, based on the number of shares subject to such agreements. 

  
 12. 

 (b) In connection with a SPAC Transaction, each Holder agrees to enter into an
agreement with the SPAC and/or the Company to not transfer the Public Shares received by such Holder in connection with the SPAC Transaction (excluding (i) any Public Shares purchased in a private placement, or received in exchange for or upon
conversion of securities issued in a private placement, that is connected to or conditioned on the SPAC Transaction and (ii) any securities acquired following the consummation of the SPAC Transaction) pursuant to terms substantially similar to
the terms set forth in Section 2.11(a). 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case,
to be bound by the terms of this Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the Preferred
Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar
event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN
ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 13. 

 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions
of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the IPO, the transfer is
made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge,
or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably
satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed
sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel
to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell,
pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a notice, legal opinion or “no action” letter (x) in any transaction in
compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that, with respect to transfers under the foregoing clause (y),
each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer
is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such
Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 
 2.13
Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event or a Qualified SPAC Transaction if such Holder’s Registrable Securities are
registered for purposes of the Securities Act following such SPAC Transaction; 
 (b) such time after consummation of the IPO or SPAC
Transaction as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration (and without the requirement for the
Company to be in compliance with the current public information required under subsection (c)(1) of SEC Rule 144); 

  
 14. 

 (c) the fifth anniversary of the IPO or SPAC Transaction. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of
Directors has not reasonably determined that such Major Investor is a Competitor: 
 (a) as soon as practicable, but in any event
within 120 days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the
end of such year, starting with the Company’s 2020 fiscal year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within 45 days after the end of each quarter of each fiscal year of the Company, unaudited
statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial
statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP), and a comparison between the actual amounts
as of and for such quarter and the amounts included in the Budget (as defined below) for such quarter, with an explanation of any material differences between such amounts; 

(c) as soon as practicable, but in any event within 45 days after the end of each quarter of each fiscal year of the Company, a
statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise
of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if
any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; provided, however, that access to an online capitalization management software (such as Carta.com) that contains
the information otherwise required to be delivered under this Section 3.1(c) shall be deemed to satisfy the requirements of this Section 3.1(c), so long as the Company provides prompt notice upon such information becoming available (which
notice requirement shall be deemed satisfied if such online platform makes automatic notifications available to such Major Investor); 

(d) as soon as practicable, but in any event within 30 days of the end of each month, an unaudited income statement and statement of
cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(e) as soon as practicable, but in any event 30 days before the end of each fiscal year, a budget and business plan for the next fiscal
year approved by the Board of Directors (collectively, the “Budget”), prepared on a monthly basis and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 

(f) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major
Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade
secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and
its counsel. 

  
 15. 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date 60 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to
such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to
cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each Major Investor,
provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor, at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records;
and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated
pursuant to this Section 3.2 to provide access to any information that (i) it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
reasonably acceptable to the Company), (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel, or (iii) with respect to NEA, Lonza and Partners, if access to such information could
be withheld from NEA’s, Lonza’s or Partners’ representative, as applicable, pursuant to Section 3.3 had such information been conveyed at a meeting of the Board of Directors or through notices, minutes,
consents, and other materials that the Company provided to its directors. 
 3.3 Observer Rights. 

(a) As long as NEA owns any shares of the Series A Preferred or any Registrable Securities, the Company shall invite a representative
of NEA to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors;
provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such
representative from any meeting or portion thereof if (i) access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel or necessary
to protect highly confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or (ii) the Board of Directors determines in good faith that such Investor or its
representative is a competitor of the Company, provided that NEA shall not be considered, and neither the Company nor the Board of Directors shall determine that NEA is, a competitor of the Company if NEA does not control or substantially engage in
a business that competes with a material product, process or service in existence or being developed by the Company (of which existence or development the Company shall notify NEA). 

  
 16. 

 (b) As long as Lonza owns any shares of the Series A Preferred or any Registrable
Securities, the Company shall invite a representative of Lonza to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other
materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; provided further, that the Company reserves the right to withhold any information and
to exclude such representative from a portion of a meeting if (i) access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel or
necessary to protect highly confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or (ii) the Board of Directors determines reasonably and in good faith that Lonza
or its representative is a competitor of the Company, provided that Lonza shall not be considered, and neither the Company nor the Board of Directors shall determine that Lonza is, a competitor of the Company if Lonza does not control or
substantially engage in a business that competes with a material product, process or service in existence or being developed by the Company (of which existence or development the Company shall notify Lonza), and further provided that the parties
hereto acknowledge and agree that as of the date of this Agreement, Lonza is not a competitor of the Company and does not control and does not engage in such competitive business referred to in this clause (ii), or (iii) the Board of Directors
in good faith reasonably determines that Lonza has an actual conflict of interest with the Company with respect to such information or the matter being discussed at such portion of a meeting, it being agreed that such a determination by the Board of
Directors may only occur with respect to the following subject matter (in each case to the extent the Board of Directors determines there is such conflict of interest): (a) discussions relating to the procurement or provision of manufacturing
services to the Company; (b) the Company’s discussion or negotiation of licensing, collaboration or other research arrangements with third parties in areas or with partners that are of strategic interest to Lonza (except if such strategic
interest is due to Lonza’s interest in the Company); or (c) matters related to the Exclusive License Agreement dated September 9, 2019 by and between MEEI, the Schepens Eye Research Institute, Inc., Lonza and the Company. 

(c) As long as Partners owns any shares of the Series A Preferred or any Registrable Securities, the Company shall invite a
representative of Partners to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such
representative from any meeting or portion thereof if (i) access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel or necessary
to protect highly confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or (ii) the Board of Directors determines in good faith that such Investor or its
representative is a competitor of the Company, provided that Partners shall not be considered, and neither the Company nor the Board of Directors shall determine that Partners is, a competitor of the Company if Partners does not control or
substantially engage in a business that competes with a material product, process or service in existence or being developed by the Company (of which existence or development the Company shall notify Partners). 

(d) As long as Farallon owns any shares of Series B Preferred Stock or any Registrable Securities, the Company shall invite a
representative of Farallon to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided further, that the
Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting would reasonably be expected to adversely affect the
attorney-client privilege between the Company and its counsel or necessary to protect highly confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company). 

  
 17. 

 3.4 Termination of Information and Observer Rights. The
covenants set forth in Section 3.1, Section 3.2, and Section 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the
periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, (iii) upon the closing of a Deemed Liquidation Event, or (iv) upon the consummation of a Qualified SPAC Transaction, whichever event occurs first;
provided, however, that in the event the covenants set forth in Subsection 3.1 terminate upon a Deemed Liquidation Event, if the consideration received by the Investors in such Deemed Liquidation Event includes securities that are not
publicly traded (which, for the avoidance of doubt, shall not include contingent value rights), the Company will use commercially reasonable efforts to ensure that the Major Investors receive financial information from the acquiring company or other
successor to the Company comparable to those set forth in Section 3.1 of this Agreement. 
 3.5 Confidentiality. Each
Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the
Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a
result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to
such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective
purchaser is required to maintain the confidentiality of such information and is bound by confidentiality obligations consistent with those set forth in this Section 3.5 (other than with respect to the term),
provided that the Board of Directors has not reasonably determined that such prospective purchaser is a Competitor; (iii) to any Affiliate, any existing or prospective partner, member or stockholder, or any wholly owned subsidiary of
such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; (iv) as may otherwise be
required by law, regulation, rule, court order or subpoena, provided that (A) if such required disclosure is specifically targeted at information regarding the Company, such Investor promptly notifies the Company of such disclosure, and
(B) such Investor takes reasonable steps to minimize the extent of any such required disclosure; or (v) as requested by a regulator or self-regulatory organization. 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities other than shares of Series B Preferred Stock authorized as of the date hereof and sold pursuant to the Purchase Agreement, the Company shall first offer such New Securities to each Major
Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself and (ii) its Affiliates; provided that each such Affiliate
(x) is not a Competitor or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, (y) agrees to enter into this Agreement and each of the Amended and Restated Voting Agreement
and Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each
such agreement (provided that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor under Sections 3.1, 3.2 and 4.1 hereof), and (z) agrees to purchase at least such number of New Securities as are
allocable hereunder to the Major Investor holding the fewest number of Preferred Stock and any other Derivative Securities. 

  
 18. 

 (a) The Company shall give notice (the “Offer Notice”) to each
Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within 20 days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including, without limitation, all shares
of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then
outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such 20 day period, the Company shall promptly notify each Major Investor that
elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the 10 day period commencing after the Company has given such
notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to
subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any
other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative
Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of 90 days of the date that the Offer Notice is given
and the date of initial sale of New Securities pursuant to Section 4.1(c). 
 (c) If all New Securities referred to in the Offer
Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the 90 day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed
portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New
Securities within such period, or if such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the
Major Investors in accordance with this Section 4.1. 
 (d) The right of first offer in this Section 4.1 shall not be
applicable to (i) Exempted Securities (as defined in the Certificate of Incorporation) or (ii) shares of Common Stock issued in the IPO. 

  
 19. 

 4.2 Termination. The covenants set forth in Section 4.1 shall terminate
and be of no further force or effect (i) immediately before the consummation of the IPO or the Qualified SPAC Transaction, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of
the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, whichever event occurs first. 
 5. Additional
Covenants. 
 5.1 Insurance. The Company shall use commercially reasonable efforts to cause the existing Directors and
Officers liability insurance to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. The policy will not be cancelable by the Company without prior approval by the Board of Directors.
Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as any Preferred Director is serving on the Board of Directors, the Company shall (a) not cease to maintain a Directors and Officers liability insurance
policy in an amount of at least two million dollars unless approved by each Preferred Director then serving, if any, and (b) no later than thirty (30) calendar days after each expiration or renewal date of such Directors and Officers
liability insurance policy, deliver to each Investor that designated a Preferred Director then serving on the Board of Directors a copy of the new or renewed Directors and Officers liability insurance policy (and evidence of such renewal, if
applicable) and written confirmation that such policy remains in effect. 
 5.2 Employee Agreements. The Company will cause
(i) each Person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) to confirm their status as either an at-will
employee or consultant/independent contractor, (ii) enter into a nondisclosure and proprietary rights assignment agreement; and (iii) enter into a one year non-solicitation agreement, substantially
in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above referenced agreements or any restricted stock agreement between the Company
and any employee without the consent of a majority of the Preferred Directors then serving, if any. 
 5.3 Employee Stock. All
future purchases or grants of options to purchase the Company’s capital stock, or awards of the Company’s capital stock, to employees or consultants of the Company shall be approved by the Board of Directors, including a majority of the
Preferred Directors then serving, if any. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital
stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four year period, with the first 25% of such shares vesting following 12 months of
continued employment or service, and the remaining shares vesting in equal monthly installments over the following 36 months, and (ii) a market stand-off provision substantially similar to that in
Section 2.11. Without the prior approval by the Board of Directors, including a majority of the Preferred Directors then serving, if any, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock
purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be inconsistent with this Section 5.3. In addition, unless otherwise approved by the Board of Directors,
including a majority of the Preferred Directors then serving, if any, the Company shall retain (and not waive) a “right of first refusal” on employee transfers until the consummation of the IPO or the Qualified SPAC Transaction and shall
have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

  
 20. 

 5.4 Board Matters. Unless otherwise determined by the vote of a majority of
the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings or any other activities of the Board of Directors that are requested by the
Company and involve expenses. As soon as reasonably practicable, the Company shall cause to be established and will thereafter maintain, a compensation committee, which shall include at least two of the Preferred Directors then serving, if any, for
the purposes of, among other things, reviewing and determining the compensation of the Company’s executive officers. Each non-employee director shall be entitled in such person’s discretion to be a
member of any committee of the Board of Directors. 
 5.5 Successor Indemnification. If the Company or any of its successors or
assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and
assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be. 
 5.6 Indemnification Matters. The Company
hereby acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by one or more of the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of
expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort
(i.e., its obligations to any such Investor Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are
secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf
of any such Investor Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights
such Investor Director may have against the Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or
any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has
sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor
Director against the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this Section 5.6 and shall have the right, power and authority to enforce the
provisions of this Section 5.6 as though they were a party to this Agreement. 
 5.7 Right to Conduct Activities. The Company
hereby agrees and acknowledges that each of NEA, F-Prime, Atlas, Farallon, EcoR1, RA Capital, TCG and Perceptive (each, a “Fund Investor”) (in each case, together with its respective
Affiliates) is a professional investment organization, and as such each Fund Investor and Lonza review the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the
Company’s business (as currently conducted or as currently propose to be conducted). Nothing in this Agreement shall preclude or in any way restrict the Investors from evaluating or purchasing securities, including publicly traded
securities, of a particular enterprise, or investing in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company; and the Company hereby agrees that, to the extent permitted under
applicable law, each Fund Investor and Lonza (and their respective Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Fund Investor or Lonza, respectively (or their respective
Affiliates), in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of such Fund Investor or Lonza, respectively (or their respective Affiliates), to assist any such
competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing
shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from
any liability associated with his or her fiduciary duties to the Company. 

  
 21. 

 5.8 Expenses of Counsel. In the event of a transaction which is a Sale of the Company
(as defined in the Amended and Restated Voting Agreement of even date herewith among the Investors, the Company and the other parties named therein), the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the Major
Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would constitute a Sale of the Company, the Company shall
obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of
intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would
constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed to the Company’s executives and/or any one or more of the other
parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications
and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor
Counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the
Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate
agreement(s) without undue burden to the clients of Investor Counsel. 
 5.9 Harassment Policy. The Company shall maintain in effect
(i) a Code of Conduct governing appropriate workplace behavior and (ii) an Anti-Harassment and Discrimination Policy prohibiting discrimination and harassment at the Company. 

5.10 Cybersecurity. The Company shall continue to (a) identify its sensitive data and information, and restrict access (through
physical and electronic controls) to those individuals who have a need to access it and (b) implement cybersecurity solution(s) (“Cybersecurity Solutions”) designed to protect its technology and systems (including servers,
laptops, desktops, cloud, containers, virtual environments and data centers) and all data contained in such systems. The Company shall use commercially reasonable efforts to ensure that the Cybersecurity Solutions (x) are up-to-date and include industry-standard protections (e.g., antivirus, endpoint detection and response and threat hunting), (y) to the extent determined necessary by the
Company or the Board of Directors, are backed by a breach prevention warranty from the vendor certifying the effectiveness of such solutions, and (z) require the vendors to notify the Company of any security incidents posing a risk to the
Company’s information (regardless of whether information was actually compromised). The Company shall evaluate on a regular basis whether the Cybersecurity Solutions should be updated to ensure continued effectiveness and industry-standard
protections. The Company shall also educate its employees about the proper use and storage of sensitive information, including regular training as determined reasonably necessary by the Company or the Board of Directors. 

  
 22. 

 5.11 FIRPTA Compliance. The Company shall provide prompt notice to each Fund Investor
and NEA Ventures 2019, Limited Partnership (each a “FIRPTA Notice Entity”) following any “determination date” (as defined in Treasury Regulation Section 1.897-2(c)(1)) on which
the Company becomes a United States real property holding corporation. In addition, upon a written request by a FIRPTA Notice Entity, the Company shall provide such FIRPTA Notice Entity with a written statement informing such FIRPTA Notice Entity
whether its interest in the Company constitutes a United States real property interest. The Company’s determination shall comply with the requirements of Treasury Regulation Section 1.897-2(h)(1) or
any successor regulation, and the Company shall provide timely notice to the Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any
successor regulation, that such statement has been made. The Company’s written statement to a FIRPTA Notice Entity shall be delivered to such FIRPTA Notice Entity within 10 days of its written request therefor. The Company’s obligation to
furnish such written statement shall continue notwithstanding the fact that a class of the Company’s stock may be regularly traded on an established securities market or the fact that there is no Preferred Stock then outstanding. 

5.12 Ultra-Rare Field. Each of Lonza and MEEI agree that the definition of “Ultra-Rare Field” in Section 1.56 of the
Amended and Restated License, Collaboration and Commercialization Agreement by and between such parties, dated as of September 9, 2019, as amended to date, shall not be amended, modified or waived without the prior written consent of the
Company. 
 5.13 Termination of Covenants. The covenants set forth in this Section 5, except for Sections 5.5, 5.6 and 5.8, shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act,
(iii) upon a Deemed Liquidation Event, or (iv) upon the consummation of a Qualified SPAC Transaction, whichever event occurs first. 

6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
or (iii) after such transfer, holds at least 630,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company
is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in
a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities
held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such
Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable
transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and
conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

  
 23. 

 6.2 Governing Law. This Agreement shall be governed by the internal law of the
State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, the Uniform Electronic
Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered
in construing or interpreting this Agreement. 
 6.5 Notices. 

(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal
business hours, then on the recipient’s next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one business day after the business day of deposit
with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their
addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Legal Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently
modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, it shall be sent to 43 Foundry Ave, Suite 120, Waltham, Massachusetts 02453, Attention: Robert Aboud, Email: raaboud@affiniatx.com;
and a copy (which shall not constitute notice) shall also be sent to Cooley LLP, 500 Boylston Street, 14th Floor, Boston, MA 02116-3736, Attention: Ryan S. Sansom, Email: rsansom@cooley.com. 

(b) Consent to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General
Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the facsimile number set
forth below such Investor’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of electronic transmission is returned or
undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given.
Each Investor agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing. 

  
 24. 

 6.6 Amendments and Waivers. Any term of this Agreement may be amended,
modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Preferred Majority
(as defined in the Certificate of Incorporation); provided further that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a
proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any
other party. Notwithstanding the foregoing: (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless
such amendment, modification, termination, or waiver applies to all Investors in the same fashion and does not adversely affect the rights of any Investor in a manner disproportionate to any adverse effect such amendment, modification, termination,
or waiver has on the rights of other parties hereto (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by
it terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction; provided that in the event any Major Investor (including its Affiliates) purchases any New
Securities in any issuance of New Securities by the Company following an amendment, modification or waiver of Section 4 or the definition of “Additional Shares of Common Stock” under the Certificate of Incorporation (a
“Participating Investor”), then each other Major Investor shall be given the opportunity, with notice of at least eight (8) business days, to participate in such offering and to purchase the same proportion (up to 100%) of such
Major Investor’s pro rata share of the New Securities being offered by the Company in the relevant transaction as is being purchased by the Participating Investor purchasing the largest proportion of such Participating Investor’s pro rata
share; provided further that each Major Investor’s pro rata participation amount shall in no event exceed the amount such Major Investor would have been entitled to purchase pursuant to Section 4 notwithstanding such waiver;
(b) the definition of “Affiliate” set forth in Section 1.1 and this clause (b) may only be amended with the written consent of F-Prime; (c) Sections 1.6(b), 1.13, 3.3(d) and
5.7 and this clause (c), in each case as it relates to Farallon, may only be amended, modified or waived with the written consent of Farallon; (d) Section 5.11 and this clause (d) may only be amended with the written consent of NEA;
(e) Section 1.6(b) and Section 5.7, in each case as it relates to RA Capital, may only be amended, modified or waived with the written consent of RA Capital; and (f) Schedule A hereto may be amended by the Company from time to
time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties, and information regarding any additional Investor who becomes a party to this Agreement in accordance with
Section 6.9. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any
amendment, modification, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition,
or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will
be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares of Registrable
Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliates may apportion such rights as among themselves in any manner they deem
appropriate. 

  
 25. 

 6.9 Additional Investors. Notwithstanding anything to the contrary contained
herein, if the Company issues additional shares of Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to
this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional
Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement.
This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no
further force or effect. 
 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the
jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree
not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to
assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or
execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE
OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT
RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH
OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or Omissions. No delay or omission to exercise
any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be
construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

[Remainder of page intentionally left blank] 

  
 26. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	COMPANY: 
	
	AFFINIA THERAPEUTICS INC.
		
	By:	 	 /s/ Rick Modi

		 	Name:	 	Rick Modi
		 	Title:	 	Chief Executive Officer

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR: 
		
	By:	 	 /s/ Rick Modi

		 	Name:	 	Rick Modi

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR: 
		
	By:	 	 /s/ Robert A. Aboud

		 	Name:	 	Robert A. Aboud

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	 NEW ENTERPRISE ASSOCIATES 17, L.P.

BY:  NEA PARTNERS 17, L.P., ITS GENERAL
PARTNER
 BY:  NEA 17 GP, LLC, ITS GENERAL
PARTNER

		
	By:	 	 /s/ Louis Citron

		 	Name:	 	Louis Citron
		 	Title:	 	Director

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	NEA VENTURES 2019, LIMITED PARTNERSHIP
		
	By:	 	 /s/ Louis Citron

		 	Name:	 	Louis Citron
		 	Title:	 	Vice President

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	 F-PRIME CAPITAL PARTNERS
LIFE SCIENCES FUND VI LP
 BY:  F-PRIME CAPITAL PARTNERS LIFE SCIENCES ADVISORS FUND VI LP, ITS GENERAL
PARTNER
 BY:  IMPRESA HOLDINGS LLC,
ITS GENERAL PARTNER

BY:  IMPRESA MANAGEMENT LLC, ITS
MANAGING MEMBER

		
	By:	 	 /s/ Mary Bevelock Pendergast

		 	Name:	 	Mary Bevelock Pendergast
		 	Title:	 	Vice President

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	 ATLAS VENTURE FUND XI, L.P.

BY:  ATLAS VENTURE ASSOCIATES XI, L.P.,
ITS GENERAL PARTNER

BY:  ATLAS VENTURE ASSOCIATES XI, LLC,
ITS GENERAL PARTNER 

		
	By:	 	 /s/ Ommer Chohan

		 	Name:	 	Ommer Chohan
		 	Title:	 	Chief Financial Officer

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	 PARTNERS INNOVATION FUND II, L.P.

BY: Partners Innovation II, LLC, ITS GENERAL PARTNER

		
	By:	 	 /s/ Roger Kitterman

		 	Name:	 	Roger Kitterman
		 	Title:	 	Partner

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	PARTNERS INNOVATION FUND, LLC
		
	By:	 	 /s/ Roger Kitterman

		 	Name:	 	Roger Kitterman
		 	Title:	 	Partner

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	MASSACHUSETTS EYE AND EAR INFIRMARY
		
	By:	 	 /s/ Roger Kitterman

		 	Name:	 	Roger Kitterman
		 	Title:	 	Vice President

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	LONZA HOUSTON, INC.
		
	By:	 	 /s/ Anthony Branciforte

		 	Name:	 	Anthony Branciforte
		 	Title:	 	Vice President

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
		
	By:	 	 /s/ Luc Vandenberghe

		 	Name:	 	Luc Vandenberghe

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
		
	By:	 	 /s/ Sean Nolan

		 	Name:	 	Sean Nolan

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	 ECOR1 CAPITAL FUND, L.P.

  
 By: EcoR1 Capital, LLC, its
General Partner

		
	By:	 	 /s/ Oleg Nodelman

		 	Name:	 	Oleg Nodelman
		 	Title:	 	Manager
	
	 ECOR1 CAPITAL FUND QUALIFIED, L.P. 
  

By: EcoR1 Capital, LLC, its General Partner

		
	By:	 	 /s/ Oleg Nodelman

		 	Name:	 	Oleg Nodelman
		 	Title:	 	Manager
	
	 ECOR1 VENTURE OPPORTUNITY FUND, L.P. 
  
 By: Biotech Opportunity GP,
LLC, its General Partner

		
	By:	 	 /s/ Oleg Nodelman

		 	Name:	 	Oleg Nodelman
		 	Title:	 	Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	ZONE III HEALTHCARE HOLDINGS, LLC
		
	 By: 
	 	 Farallon Capital Management, L.L.C.,

its Manager

		
	By:	 	 /s/ Philip Dreyfuss

		 	Name:	 	Philip Dreyfuss
		 	Title:	 	Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	By: RA Capital Healthcare Fund GP, LLC
	Its General Partner
		
	By:	 	 /s/ Rajeev Shah

	Name: Rajeev Shah
	Title:   Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL NEXUS FUND II, L.P.
	
	By: RA Capital Nexus Fund II GP, LLC
	Its: General Partner
		
	By:	 	 /s/ Rajeev Shah

	Name: Rajeev Shah
	Title: Manager

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTORS:
	
	 OCTAGON INVESTMENTS MASTER FUND LP
  

By: Octagon Capital Advisors, LP
 Its Investment
Manager

		
	By:	 	 /s/ Ting Jia

		 	Name:	 	Ting Jia
		 	Title:	 	Managing Member
	
	 OCTAGON PRIVATE OPPORTUNITIES FUND LP
  

By: Octagon Capital Advisors, LP
 Its Investment
Manager

		
	By:	 	 /s/ Ting Jia

		 	Name:	 	Ting Jia
		 	Title:	 	Managing Member

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTORS:
	
	 CASDIN PRIVATE GROWTH EQUITY FUND, L.P.
  

By: Casdin Private Growth Equity Fund GP, LLC, its General Partner

		
	By:	 	 /s/ Kevin O’Brien

		 	Name:	 	Kevin O’Brien
		 	Title:	 	General Counsel
	
	 CASDIN PARTNERS MASTER FUND, L.P.
  

By: Casdin Partners GP, LLC, its General Partner

		
	By:	 	 /s/ Kevin O’Brien

		 	Name:	 	Kevin O’Brien
		 	Title:	 	General Counsel

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	 TCG CROSSOVER FUND I, L.P.

 
 By: TCG Crossover GP I, LLC

Its General Partner

		
	By:	 	 /s/ Chen Yu

		 	Name:	 	Chen Yu
		 	Title:	 	Managing Member

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

			
	INVESTOR:
	
	GV 2021, L.P.
	By: GV 2021 GP, L.P., its General Partner
	By: GV 2021 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

	Name: Daphne M. Chang
	Title: Authorized Signatory

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of
the date first written above. 
  

					
	INVESTOR:
	
	 PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors, LLC

		
	By:	 	 /s/ James H. Mannix

		 	Name:	 	James H. Mannix
		 	Title:	 	COO

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	 WOODLINE PARTNERS
 By:
Woodline Partners LP, its Manager

		
	By:	 	 /s/ Matthew Hooker

		 	Name:	 	Matthew Hooker
		 	Title:	 	Managing Member of Woodline Fund GP LLC, its General Partner

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

					
	INVESTOR:
	
	AVIDITY MASTER FUND LP
		
	By:	 	 /s/ Michael Gregory

		 	Name:	 	Michael Gregory
		 	Title:	 	Director

  

					
	AVIDITY CAPITAL FUND II LP
		
	By:	 	 /s/ Michael Gregory

		 	Name:	 	Michael Gregory
		 	Title:	 	Director

 SCHEDULE A 

INVESTORSEX-10.1

 Exhibit 10.1 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 EXCLUSIVE LICENSE AGREEMENT 

BETWEEN 
 LONZA HOUSTON,
INC. 
 AND 

MASSACHUSETTS EYE AND EAR INFIRMARY AND 

THE SCHEPENS EYE RESEARCH INSTITUTE, INC. 

AND 
 TDTX, INC.

 September 9, 2019 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
		
	 ARTICLE 2 GRANT OF LICENSES, RESERVED RIGHTS AND SUBLICENSING
	  	 	10	 
			
	 2.1
	  	License Grant	  	 	10	 
			
	 2.2
	  	Responsibility for Affiliates and Sublicensees	  	 	10	 
			
	 2.3
	  	No Implied Licenses	  	 	10	 
			
	 2.4
	  	Reserved Rights	  	 	11	 
			
	 2.5
	  	Sublicensing	  	 	11	 
			
	 2.6
	  	Option to License Arising Patent Rights after the Effective Date	  	 	12	 
			
	 2.7
	  	MEE’s Ophthalmology Target Option	  	 	13	 
		
	 ARTICLE 3 FINANCIAL TERMS
	  	 	14	 
			
	 3.1
	  	Equity	  	 	14	 
			
	 3.2
	  	Milestone Payments	  	 	16	 
			
	 3.3
	  	Royalties	  	 	17	 
			
	 3.4
	  	Offsets from Royalty Payments; Minimum Royalty Rates	  	 	18	 
			
	 3.5
	  	[Reserved]	  	 	18	 
			
	 3.6
	  	Payment	  	 	18	 
			
	 3.7
	  	Sublicense Income	  	 	18	 
			
	 3.8
	  	Reduction of Sublicense Income Fees Payable to Licensors [***]	  	 	19	 
			
	 3.9
	  	Patent Expenses	  	 	20	 
			
	 3.10
	  	Waiver or Deferral	  	 	20	 
			
	 3.11
	  	Form of Payments and Taxes	  	 	20	 
			
	 3.12
	  	Currency Conversion	  	 	21	 
			
	 3.13
	  	Interest	  	 	21	 
			
	 3.14
	  	Right to Offset	  	 	21	 
		
	 ARTICLE 4 ROYALTY REPORTS, PAYMENTS AND FINANCIAL RECORDS
	  	 	21	 
			
	 4.1
	  	Royalty Reports	  	 	21	 
			
	 4.2
	  	Record Keeping	  	 	22	 
		
	 ARTICLE 5 JOINT STEERING COMMITTEE
	  	 	22	 
			
	 5.1
	  	Formation and Representatives	  	 	22	 
			
	 5.2
	  	JSC Chairman	  	 	22	 
			
	 5.3
	  	Meetings by the JSC	  	 	22	 
		
	 ARTICLE 6 OPERATIONS UNDER THE LICENSE
	  	 	23	 
			
	 6.1
	  	Diligence Obligations	  	 	23	 
			
	 6.2
	  	Minimum Capital Funding	  	 	24	 
			
	 6.3
	  	Minimum Potential Revenue Stream Requirements	  	 	25	 

  
 i. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 6.4
	  	Regulatory Matters	  	 	26	 
			
	 6.5
	  	Other Government Laws	  	 	26	 
			
	 6.6
	  	Patent Marking	  	 	26	 
			
	 6.7
	  	Ongoing Communication	  	 	26	 
		
	 ARTICLE 7 TDTX-LONZA STRATEGIC
MANUFACTURING RELATIONSHIP
	  	 	26	 
			
	 7.1
	  	Manufacturing Agreements	  	 	26	 
		
	 ARTICLE 8 CONFIDENTIALITY
	  	 	26	 
			
	 8.1
	  	Non-Disclosure Obligation	  	 	26	 
			
	 8.2
	  	Government-Required Disclosure	  	 	27	 
		
	 ARTICLE 9 INTELLECTUAL PROPERTY
	  	 	27	 
			
	 9.1
	  	Ancestral Technology Patent Preparation, Filing, Prosecution and Maintenance.	  	 	27	 
			
	 9.2
	  	Election Not to File and Prosecute Patent Rights	  	 	28	 
			
	 9.3
	  	Notice	  	 	28	 
			
	 9.4
	  	Relinquishing Rights	  	 	28	 
			
	 9.5
	  	Intellectual Property Rights	  	 	28	 
		
	 ARTICLE 10 PATENT INFRINGEMENT AND ENFORCEMENT
	  	 	29	 
			
	 10.1
	  	Notice	  	 	29	 
			
	 10.2
	  	Enforcement	  	 	29	 
			
	 10.3
	  	Distribution of Amounts Paid by Third Parties	  	 	30	 
			
	 10.4
	  	Declaratory Judgment or Infringement Actions	  	 	30	 
			
	 10.5
	  	Delegation	  	 	31	 
		
	 ARTICLE 11 TERM AND TERMINATION
	  	 	31	 
			
	 11.1
	  	Term	  	 	31	 
			
	 11.2
	  	Termination by Licensors	  	 	31	 
			
	 11.3
	  	Termination by TDTx	  	 	32	 
			
	 11.4
	  	Material Breach Dispute	  	 	32	 
			
	 11.5
	  	Effect of Termination	  	 	32	 
		
	 ARTICLE 12 INDEMNIFICATION AND INSURANCE
	  	 	33	 
			
	 12.1
	  	Indemnification	  	 	33	 
			
	 12.2
	  	Insurance	  	 	35	 
			
	 12.3
	  	Disclaimer of Warranties; Limitation of Liability	  	 	35	 
			
	 12.4
	  	Acknowledgement	  	 	36	 
			
	 12.5
	  	Article Survival	  	 	36	 
		
	 ARTICLE 13 REPRESENTATIONS AND WARRANTIES
	  	 	36	 
			
	 13.1
	  	TDTx’s Representations and Warranties	  	 	36	 

  
 ii. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
			
	 13.2
	  	Lonza’s Representations and Warranties and Covenants	  	 	36	 
			
	 13.3
	  	MEE’s Representations	  	 	37	 
		
	 ARTICLE 14 NOTICES
	  	 	37	 
			
	 14.1
	  	Notices to Lonza	  	 	37	 
			
	 14.2
	  	Notices to MEE	  	 	37	 
			
	 14.3
	  	Notices to TDTx	  	 	37	 
		
	 ARTICLE 15 DISPUTE RESOLUTION
	  	 	38	 
			
	 15.1
	  	Negotiation between the Parties	  	 	38	 
			
	 15.2
	  	Arbitration	  	 	38	 
			
	 15.3
	  	Governing Law	  	 	38	 
		
	 ARTICLE 16 FORCE MAJEURE
	  	 	39	 
		
	 ARTICLE 17 ASSIGNABILITY
	  	 	39	 
		
	 ARTICLE 18 MISCELLANEOUS
	  	 	39	 
			
	 18.1
	  	MEE Policies	  	 	39	 
			
	 18.2
	  	Relationship of Parties	  	 	40	 
			
	 18.3
	  	Further Actions	  	 	40	 
			
	 18.4
	  	Use of Name; Publicity	  	 	40	 
			
	 18.5
	  	Waiver	  	 	40	 
			
	 18.6
	  	Severability	  	 	40	 
			
	 18.7
	  	Amendment	  	 	40	 
			
	 18.8
	  	Entire Agreement	  	 	40	 
			
	 18.9
	  	Parties in Interest	  	 	40	 
			
	 18.10
	  	Descriptive Headings	  	 	40	 
			
	 18.11
	  	Counterparts	  	 	41	 
			
	 18.12
	  	No Presumption	  	 	41	 
			
	 18.13
	  	Interpretation	  	 	41	 

  
 iii. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED

 BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

EXCLUSIVE LICENSE AGREEMENT 

THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”),
effective as of September 9, 2019 (“Effective Date”), is made between Lonza Houston, Inc., a Delaware corporation having a principal place of business at 14905 Kirby Drive, Houston, Texas 77047, United States,
(“Lonza”) and Massachusetts Eye and Ear Infirmary, a not-for-profit Massachusetts corporation, having its principal place of business at 243
Charles Street, Boston, MA 02114, and The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having its principal place of business at 20
Staniford Street, Boston, MA 02114 (collectively “MEE”) (Lanza and MEE are collectively referred to herein as “Licensor(s)”), and TDTx Inc., a Delaware corporation having a principal place of business
at One Broadway, 14th Floor, Kendall Square, Cambridge, MA 02142 (“TDTx” or “Licensee”). Lonza, MEE, and TDTx shall hereinafter collectively be referred to as the “Parties” and
each, individually, as a “Party”. 
 BACKGROUND 

WHEREAS, MEE owns or Controls certain Intellectual Property related to the Ancestral Technology; and 

WHEREAS, MEE has granted certain exclusive license rights under such Intellectual Property related to the
Ancestral Technology to Lonza pursuant to that certain License, Collaboration and Commercialization Agreement between MEE and Lonza dated as of [***] (the “Original Lonza-MEE
Agreement”), as such agreement is being amended and restated concurrently with the execution of this Agreement (the “Amended and Restated Lonza-MEE Agreement”), and MEE has
retained certain rights and certain fields of use under the Intellectual Property related to the Ancestral Technology that were not granted to Lonza under the Amended and Restated Lonza-MEE Agreement; and 

WHEREAS, Licensee desires to obtain an exclusive license for all fields of use (except for the Excluded
Field of Use and the Excluded Targets, as each is defined herein) under the Licensed Intellectual Property and Licensors are willing to grant such a license to Licensee in view of the Amended and Restated
Lonza-MEE Agreement and upon the terms and conditions stated under this Agreement, without the limitations and restrictions on the scope of the licensed field of use or on the right to grant sublicenses or the
scope of any permitted sublicenses that existed under the Original Lonza-MEE Agreement, all in order to enable TDTx to have a license to, and to grant broad sublicenses within the Field of Use (except for the
Excluded Field of Use and the Excluded Targets, as each is defined herein); and 
 WHEREAS, Licensee
has represented to Licensors that it has or will have the capabilities and/or experience to develop, produce, market and sell products utilizing technology that is the subject of this Agreement and has or will have the financial capacity and the
strategic commitment to facilitate the transfer of the technology for the public interest. 
 NOW THEREFORE, Lonza, MEE and TDTx, each
intending to be legally bound, do hereby agree as follows. 
 ARTICLE 1 

DEFINITIONS 
 The
capitalized terms used herein shall have the meanings set forth below in this Article 1 unless otherwise expressly defined in this Agreement. 

1.1 “Affiliate” means any company, corporation or other business entity that is controlled by, controlling, or
under common control of a Party, for so long as such control exists. For this purpose “control” means direct or indirect beneficial ownership of at least fifty percent (50%) interest in the voting stock (or the equivalent) of the company,
corporation or other business or having the right to direct, appoint or remove a majority of members of its board of directors (or their equivalents) or having the power to control the general management of the company, corporation or other
business, by law or contract; provided, however, that a business entity whose primary business is the investment in other companies shall not be deemed to “control” a Party. 

  
 1. 

 1.2 “Ancestral Technology” means all compositions, methods,
processes, tools, protocols, technical information and other technology related to and including the identified [***] and [***] sequences and any variants and all [***] created or identified from such technology, in each case solely to the extent
that such technology is disclosed in PCT application [***] and/or [***] 
 1.3 “Ancestral Technology Intellectual
Property” means the Ancestral Technology Know How and Ancestral Technology Patent Rights. 
 1.4 “Ancestral
Technology Know-How” means any Know-How that satisfies all of the following criteria, (a)-(d): (a) relates to the Ancestral Technology or the SRA Ancestral
Technology or the Licensed Products; (b) is necessary or useful for the exercise of the rights granted under Section 2.1 in the Field of Use in the Territory; (c) is described in Schedule E hereto; and (d) is Controlled by MEE or
Lonza as of the Effective Date or was generated under the SRA and is documented in writing on or within [***] of the Effective Date. For clarity, if any of the aforementioned Know-How is jointly owned by MEE
or Lonza and a Third Party such that MEE or Lonza does not Control all rights, title and interests therein, then Ancestral Technology Know-How includes only MEE or Lonza’s interest in such Know-How. The Ancestral Technology Know-How is limited to the Know-How that is described in Schedule E hereto as of the Effective Date,
or as may be updated within [***] of the Effective Date in accordance with Section 2.4.3. 
 1.5 “Ancestral
Technology Patent Rights” means (a) the United States provisional patent application [***], any conversion, continuation, continuation-in-part,
divisions, substitutions or foreign counterparts thereof, any patents issuing thereon, and any reissues, reexaminations, supplemental protection certificates or extensions thereof, including without limitation, the patents and patent applications
set forth in Schedule A (which Schedule A will be updated from time to time on an as needed basis) and (b) any other Patent Rights (including the Arising Patent Rights) Rights) which (i) claim or Cover the Ancestral Technology or the SRA
Ancestral Technology, (ii) are Controlled by Lonza (or by TDTx pursuant to the provisions of Section 2.6) at any time during the Term as the result of Lonza or its Affiliates (or TDTx pursuant to the provisions of Section 2.6) having
acquired or exercised rights in any Intellectual Property that is subject to a license, sublicense, or other agreement between Lonza and/or its Affiliates and MEE, in each case pursuant to the exercise of the option rights of Lonza under the SRA,
and (iii) are included in the license granted to TDTx under Section 2.1 on or after the Effective Date pursuant to the provisions of Section 2.6, wherein each of the conditions of subparts (i), (ii) and (iii) of this sentence are
met. 
 1.6 “Arising Patent Rights” shall mean any Patent Rights in any patentable invention generated under
the SRA, including the [***] Patent Rights and other patent applications arising under the SRA, each as set forth in Schedule A, which is Controlled by MEE or Lonza and is disclosed and claimed in a patent application, and all continuations,
divisions, and reissues based thereof, and any corresponding foreign patent applications and any patents, or other equivalent patents issuing, granted or registered thereon. 

  
 2. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.7 “Available Target” shall mean, for the purposes of either
(a) the exercise by an Existing Third Party Licensee/Sublicensee of any Unnamed Option, or (b) the exercise by MEE of its Ophthalmology Target Option in connection with a specific transgene or biological target, that, at the time that the
Existing Third Party Licensee/Sublicensee notifies MEE or Lonza that it wishes to specify such transgene or biological target or MEE notifies TDTx via the JSC that it desires to exercise its Ophthalmology Target Option with respect to such transgene
or biological target, such transgene or biological target is available for licensing. Unless TDTx can reasonably demonstrate to the JSC that either: (i) TDTx or its Affiliate or Sublicensee is already in bona fide, good faith term sheet
discussions with a Third Party wherein such term sheet either names or describes such biological target or transgene or otherwise includes such biological target or transgene (without naming or describing it) within the scope of the proposed
licensed field, subfield or indication(s) included under the term sheet, or for which TDTx or its Affiliate or Sublicensee has a final term sheet with a Third Party, in each case at the time in which the Existing Third Party Licensee/Sublicensee or
MEE requests to name or obtain license rights to such biological target or transgene; or (ii) TDTx or its Affiliate or Sublicensee is actively progressing or actively planning to progress such biological target or transgene in research,
development or commercial activities or is actively progressing or actively planning to progress financing activities involving such biological target or transgene (whether or not specifically named if otherwise described or included within the
relevant field, subfield or indication); or (iii) TDTx or its Affiliate or Sublicensee has already executed a binding definitive commercial license or sublicense agreement or asset purchase agreement (or other similar agreement for the transfer
or disposition of rights) with a Third Party with respect to such biological target or transgene which names, describes or otherwise includes such biological target or transgene (without naming or describing it) within the scope of the licensed
field, subfield or indication(s) included under such license or sublicense or other agreement. For clarity, if TDTx can reasonably demonstrate to the JSC that any of the conditions as described in subparts (i), (ii) or (iii) above are met at
the time that such transgene or biological target is requested, the transgene or biological target shall not be considered to be an Available Target. 

1.8 “Clinical Study” means a clinical study in human subjects that has been approved by a Regulatory Authority
and applicable institutional review board or ethics committee, and is designed to measure the safety and/or efficacy of a Licensed Product. Clinical Studies shall include, but not be limited to, Phase I Studies, Phase II Studies, Phase III Studies
and any clinical studies required to be conducted by any Regulatory Authorities following receipt of Regulatory Approval. 
 1.9
“Collaboration Partner” means a Sublicensee with whom TDTx or its Affiliate has entered into a contractual relationship, to collaborate in the performance of any research, development and/or commercial activities, such as
[***]. In no event may any entity whose role in the partnership is a Competing Contract Manufacturer be deemed to be a Collaboration Partner for the purposes of this Agreement nor shall any entity which merely receives a sublicense under the
Licensed Intellectual Property without such contractual relationship having any of the elements of a collaboration as described in this paragraph. 

1.10 “Combination Product” means any biopharmaceutical product that consists of a component that is a Licensed
Product and [***]. If a Licensed Product is sold as part of a Combination Product in a country in the Territory, Net Sales for the Licensed Product included in such Combination Product in such country shall be calculated as follows: 

(a) If the Licensed Product is sold separately in such country and the other active ingredient(s) or product(s) in the Combination
Product are sold separately in such country, Net Sales for the Licensed Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/(A+B), where A is the invoice price of the Licensed
Product when sold separately in such country and B is the total invoice price of the other active ingredient(s) or product(s) in the Combination Product when sold separately in such country; 

(b) If the Licensed Product is sold separately in such country but the other active ingredient(s) or product(s) in the Combination
Product are not sold separately in such country, Net Sales for the Licensed Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/D, where A is the invoice price of the Licensed
Product when sold separately in such country and D is the invoice price of the Combination Product in such country; 
 (c) If the
Licensed Product is not sold separately in such country but the other active ingredient(s) or product(s) in the Combinations Product are sold separately in such country, Net Sales for the Licensed Product shall calculated by multiplying actual Net
Sales of such Combination Product by the fraction 1 – (B/D), where B is the invoice price of the other active ingredient(s) or product(s) in the Combination Product when sold separately in such country and D is the invoice price of the
Combination Product in such country; or 

  
 3. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) If neither the Licensed Product nor the other active ingredient(s) or product(s)
in the Combination Product are sold separately in such country, the Parties shall [***]. 
 1.11 “Commercially Reasonable
Efforts” means the level of efforts and resources (including the promptness with which such efforts and resources would be applied) consistent with the efforts and resources normally used by a similarly situated (i.e., in terms of size,
stage and resources) biopharmaceutical, biotech or pharmaceutical (as applicable) company in the exercise of commercially reasonable business discretion relating to the research, development, manufacture, or commercialization of a biopharmaceutical
product with similar product characteristics that is of similar market potential at a similar stage of development or commercialization, taking into account issues such as efficacy, safety, product profile, anticipated or approved labeling, present
and future risk-adjusted market potential, competitive market conditions, the proprietary position of the drug substance or product, the regulatory factors and structure involved, and other key technical, legal, scientific, medical or commercial
factors, and the risk-adjusted potential profitability of the product. 
 1.12 “Competing Contract
Manufacturer” shall mean any Third Party listed in Schedule G, which may be amended from time-to-time to remove any Third Party listed that both Lonza and
TDTx agree is no longer a Competing Contract Manufacturer, as such criteria is defined below in both (i) and (ii), or any other Third Party provider of
fee-for-service contract manufacturing services that Lonza proposes to add to Schedule G after the Effective Date which Lonza can demonstrate by credible evidence in
writing, that, at the time that Lonza proposes to add the Third Party to the list in Schedule G, which shall be at least [***] prior to the time of the proposed assignment of this Agreement by TDTx under Article 17: (i) [***], and (ii) [***], such
that in all cases both (i) and (ii) are met. 
 1.13 “Compulsory License” means a compulsory license
under the Licensed Intellectual Property obtained by a Third Party through the order, decree, or grant of a competent governmental body or court, authorizing such Third Party to develop, make, have made, use, sell, offer to sell, import or otherwise
exploit a Licensed Product or a product equivalent to a Licensed Product in the Field of Use in any country in the Territory. 
 1.14
”Confidential Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas,
instructions, skills, techniques, procedures, specifications, data, results and other material, pre-clinical and Clinical Study results, manufacturing procedures, test procedures and purification and isolation
techniques, and any tangible embodiments of any of the foregoing, and any scientific, manufacturing, marketing and business plans, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers,
customers, employees, investors or business, furnished by one Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) on or after the Effective Date. Without limiting the foregoing,
the terms of this Agreement will be deemed “Confidential Information” of both Parties and will be subject to the terms and conditions set forth in Article 7, and all records and reports delivered by TDTx to Licensors
hereunder shall be the Confidential Information of TDTx. 
 1.15 “Contract Year” shall mean each calendar
year period during the Term; provided, however, that the first such Contract Year shall commence on the Effective Date and end one year thereafter with the last such Contract Year ending on the final day of the Term.
“Contract Year One” shall mean the first such year; “Contract Year Two” shall mean the second such year, and so on,
year-by-year. 
 1.16
“Control” or “Controlled” means, with respect to rights in any Intellectual Property, that a Party owns or has a license or sublicense to such rights and has the right and ability to grant an exclusive
license. or sublicense thereto as provided for in this Agreement, without violating the terms of any agreement or other arrangement with any Third Party, and without payment of any additional consideration to such Third Party. 

1.17 “Cover”, “Covering” or “Covered” means, with respect to a
Licensed Product, that the manufacture, use or sale of the Licensed Product would, but for a license granted in this Agreement, infringe a Valid Claim of the Ancestral Technology Patent Rights in the country in which the manufacture, use or sale
occurs. 

  
 4. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.18 “Excluded Field of Use” shall mean (i) the
treatment, palliation, prevention or diagnosis of any retinal disease, disorder or condition in humans in the Ultra-Rare Field [***], or (ii) the treatment, diagnosis, prevention and palliation of any and all balance disorders or diseases
pertaining to the inner ear and/or any and all hearing diseases or disorders, including hearing disorders of the inner ear. For clarity with respect to (ii), in the case of any disorders or diseases affecting balance, hearing or the inner ear which
also affect other sensory perceptions, organs or tissues, the Excluded Field of Use will only include such disorders or diseases to the extent pertaining to balance, hearing or the inner ear. 

1.19 “Excluded Targets” shall mean only those certain specific transgenes or targets for which Lonza or MEE has
already licensed such transgenes or targets under a commercial license agreement or provided exclusive rights under an Existing Option Agreement with respect to such transgenes or targets prior to or within [***] of the Effective Date of this
Agreement under an Existing Third Party License/Sublicense Agreement. At the request of TDTx, Lonza or MEE (as applicable) will use good faith reasonable efforts to obtain consent from the applicable Third Party to disclose, under appropriate
written confidentiality obligations, the identity of the relevant Excluded Target(s) under the relevant Existing Third Party License/Sublicense Agreement via an employee representative to be designated by Lonza or MEE as the authorized discloser
(“Gatekeeper”) of such confidential information regarding the identity of the transgenes or targets that are Excluded Target(s) hereunder. 

1.20 “Existing Third Party Licensee/Sublicensee” means, separately and collectively, each of the Third Parties
who have entered into Existing Third Party License/Sublicense Agreements. 
 1.21 “Existing Third Party License/Sublicense
Agreements” means those certain license or sublicense agreements as listed on Schedule F as of the Effective Date, in which either MEE or Lonza provides a commercial license or commercial sublicense rights to an Existing Third Party
Licensee/Sublicensee for the use of the Ancestral Technology (or a subset thereof) in connection specifically with and limited to use for one or more specified Excluded Targets or rights under an Existing Option Agreement, in the form that such
agreements exist as of the Effective Date or as agreed between the Parties related to advanced negotiations between Lonza and a Third Party for such a binding definitive sublicense agreement prior to the Effective Date but which are anticipated to
be executed within [***] after the Effective Date, or for any mutually-agreed extension beyond such [***] period that is mutually agreed in writing by each of MEE, Lonza and TDTx, such extension not to exceed [***] beyond the expiration of the [***]
period. For clarity, any such binding definitive sublicense agreements that are executed within such [***] period shall be deemed included under this definition. Also for clarity, the Existing Third Party License/Sublicense Agreements do not include
any research evaluation agreements that provide rights of use or licenses solely for limited internal research or evaluation purposes only and which do not provide any license rights or option rights for any development or commercial use (each such
agreement, a “Research Evaluation Agreement”). 
 1.22 “Existing Option Agreements”
means those certain option agreements listed on Schedule F as of the Effective Date in which either MEE or Lonza provides options to acquire commercial sublicense rights to an Existing Third Party Licensee/Sublicensee for the use of one or more
specified (or to be specified after the Effective Date of this Agreement pursuant to existing option rights that were granted as of the Effective Date of this Agreement, each an “Unnamed Option”) transgenes or biological
targets meets the definition of Available Target(s). 
 1.23 “Field of Use” means the use of a Licensed
Product in any and all fields of use, but excluding only the Excluded Field of Use and the Excluded Targets; provided, however, that the Excluded Targets shall be excluded only for the limited field(s) that are/were specifically
licensed under the applicable Existing Third Party License/Sublicense Agreement. 

  
 5. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.24 “First Commercial Sale” means the initial transfer of a
Licensed Product in a country [***] by or on behalf of TDTx, an Affiliate or Sublicensee for cash or non-cash consideration to which a fair market value can be assigned for purposes of determining Net Sales.

 1.25 “Initiation” means, with respect to a Clinical Study, the date on which a Clinical Study opens for
patient accrual at one clinical centre with all then-applicable required Regulatory Approvals and institutional approvals. 
 1.26
“Intellectual Property” means all intellectual property and forms of protection directed thereto worldwide arising under statutory or common law, and whether or not perfected, including, without limitation, the following:

 (a) Patent Rights; 

(b) all works of authorship including copyrights, copyright applications, copyright registrations, mask works, mask work applications,
and mask work registrations, including, but not limited to, any software, software code, source code, and user interfaces and rights associated therewith; 

(c) trademarks, including any logos, designs, variations or translations thereof all rights associated therewith; 

(d) all rights relating to the protection of trade secrets and Confidential Information; and 

(e) all Know-How. 

1.27 “Know-How” means any technical and other information which is not
generally available to the public, including ideas, concepts, trade secrets, inventions (whether or not patentable), discoveries, know-how, data, formulae, specifications, compositions, sequences, methods,
processes, procedures and tests and other protocols, results of experimentation and testing, fermentation and purification or process development techniques and assay protocols. 

1.28 “Licensed Intellectual Property” means, collectively, (a) the Ancestral Technology Patent, Rights,
(b) the Ancestral Technology Know-How, (c) if, when, and solely to the extent that either Lonza and/or TDTx validly exercises the option under the SRA pursuant to the provisions of Section 2.6,
the Arising Patent Rights, and [***]. 
 1.29 “Licensed Product” means any product within the Field of Use,
which product is either (i) Covered by a Valid Claim within the Ancestral Technology Patent Rights, or (ii) a variant of a naturally occurring AAV serotype that was made through the use of a method recited in a Valid Claim within the [***]
Patent Rights to identify or design such product. 
 1.30 ”Licensed Transgene” means, solely for the purpose
of defining the scope of rights granted under the Existing Third Party License/Sublicense Agreements and the Excluded Targets, the [***]. For the purposes of this definition, [***]. 

1.31 “[***] Patent Rights” means the Patent Rights as listed in [***] of Schedule A claiming the [***] method
[***] for the identification and design of novel AAV vector compositions of matter. 
 1.32 “Lonza Intellectual
Property” means any Intellectual Property of which Lonza is the owner and which is or was discovered, invented or developed by or on behalf of Lonza prior to or during the course of, but completely separate and independent from, this
Agreement but in all cases excludes the Ancestral Technology Know-How and Ancestral Technology Patent Rights and the SRA Ancestral Technology. 

  
 6. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.33 “Major Market” shall mean [***]. 

1.34 “M&A Transaction” means any transaction or agreement or series of transactions or agreements wherein
TDTx or any of its Affiliates is acquired or undergoes a merger, consolidation or other business combination with a Third Party or otherwise undergoes a change of control, or wherein TDTx sells or transfers all or substantially all of its business
or assets pertaining to this Agreement or to any Licensed Product to a Third Party purchaser or transferee. 
 1.35 “MEE
Intellectual Property” means any Intellectual Property of which MEE is the owner and which is or was discovered, invented or developed by or on behalf of MEE prior to or during the course of, but completely separate and independent
from, this Agreement. 
 1.36 “Minimum Potential Revenue Stream Requirements” has the meaning as defined in
Section 6.3.1 of this Agreement. 
 1.37 “Net Sales” means all revenues recorded by or on behalf of TDTx
or its Affiliates or Sublicensees from sales of Licensed Products in the Field of Use in the Territory to independent or unaffiliated Third Party purchasers of such Licensed Products. The permitted deductions booked on an accrual basis by TDTx, its
Affiliates and/or its Sublicenses under their respective accounting standards to calculate the recorded net sales from gross sales are as follows: 

(a) discounts actually granted, including without limitation, quantity, trade, cash and other discounts, rebates and charge-backs
(excluding inventory management fees, discounts or credits), and, solely in the case of [***]; 
 (b) amounts refunded or credits
allowed for Licensed Products or other goods returned or not accepted by customers, including in connection with recalls (regardless of the Party requesting the recall); 

(c) packaging, freight, transportation and [***] charges related to the sale, transportation, delivery or return of Licensed Products;

 (d) taxes, tariffs, customs duties, surcharges and other governmental or non-governmental
payer’s charges and chargebacks actually incurred and paid by TDTx, its Affiliates or its Sublicensees hereunder in connection with the sale, use, exportation, importation or delivery of Licensed Products or other goods to customers; 

(e) retroactive price reductions, chargebacks and rebates made to [***]; 

(f) [***]. 
 Subject to
the qualification stated below, upon any sale or other disposal of Licensed Products by or on behalf of TDTx, its Affiliates or its Sublicensees hereunder other than a bona fide arm’s length transaction exclusively for money at market value or
upon any use of the Licensed Product for purposes which do not result in a disposal of such Licensed Product in consideration of sales revenue customary in the country of use, such sale, other disposal or use shall be deemed to constitute a sale at
the greater of the actual consideration for such sale or other disposal or the then-current [***] average selling price in the country in which such sale, other disposal or use occurs. 

Net Sales includes the fair market value of any non-cash consideration from sale of Licensed Products
received by TDTx, its Affiliates or Sublicenses. Net Sales shall exclude sales or transfers of Licensed Products [***]. 
 Licensed Products
are considered “sold” when billed, invoiced, or payment is received, whichever occurs first. 

  
 7. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.38 “Patent Rights” means: (a) an issued or granted
patent, including any extension, supplemental protection certificate, registration, confirmation, reissue, reexamination or renewal thereof; (b) a pending patent application, including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c) all counterparts or foreign equivalents of any of the foregoing issued by or filed in any
country or other fiction. 
 1.39 “Person” means any natural person, corporation, firm, business trust, joint
venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof. 

1.40 “Phase I Study” means a study of a Licensed Product in humans, the principal purpose of which is a
determination of safety, tolerability or pharmacokinetics in healthy individuals or patients in the target patient population prescribed by the relevant Regulatory Authority, from time to time, pursuant to applicable law or otherwise, including the
trials referred to in 21 C.F.R. §312.21(a), as amended. 
 1.41 “Phase I/II Study” means a Clinical
Study of a Licensed Product in humans that combines a Phase I Study and a Phase II Study into a single protocol to determine the maximum tolerable dose of the Licensed Product and to further evaluate safety and/or efficacy of such product. 

1.42 “Phase II Study” means a study of a Licensed Product in humans, the principal purpose of which is a
determination of safety and efficacy in the target patient population, which is prospectively designed to generate sufficient data that may permit commencement of a Pivotal Trial, or a similar Clinical Study prescribed by the relevant Regulatory
Authority, from time to time, pursuant to applicable law or otherwise, including the trials referred to in 21 C.F.R. §312.21(b), as amended. 

1.43 “Phase III Study” means a study of a Licensed Product in humans of the efficacy and safety of such
product, which is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular indication in a manner sufficient (alone or together with one or more other such studies) to file an application
for Regulatory Approval for the product, as further defined in 21 C.F.R. § 312.21(c) (or the equivalent thereof outside the United States). 

1.44 “Pivotal Trial” means a Clinical Study intended to provide the basis for Regulatory Approval. For clarity,
a Pivotal Trial shall include a Phase III Study, a Phase I/II Study or a later Clinical Study where the evidence from such Clinical Study is intended to be used as the basis for Regulatory Approval. 

1.45 “Potential Revenue Stream” shall mean the total of all fees and payments potentially payable under each
Sublicense Agreement executed between TDTx and a Third Party in a Contract Year, which includes, without limitation [***], but excludes [***]. 

1.46 “Regulatory Approval” means any and all approvals (including any pricing and/or reimbursement approvals),
licenses, registrations or authorizations of any Regulatory Authority that are necessary at the relevant stage of development or commercialization for the development, marketing and sale of a Licensed Product in a country or group of countries. 

1.47 “Regulatory Authority” means any applicable supra-national, federal, national, regional, state,
provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities, including the U.S. Food and Drug Administration or any successor entity thereto (“FDA”) and the European
Medicines Agency or any successor entity thereto (“EMA”), regulating or otherwise exercising authority with respect to the development, manufacture or commercialization of any Licensed Product in the Territory. 

1.48 “Royalty Term” means, on a Licensed
Product-by-Licensed Product and country-by-country basis, the period from and after the
First Commercial Sale of such Licensed Product in such country until the later to occur of (a) the last to expire Valid Claim of the Ancestral Technology Patent Rights which Covers such Licensed Product in such country and (b) ten (10)
years after the First Commercial Sale of such Licensed Product in such country. 

  
 8. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.49 “Sponsored Research Agreement” or
“SRA” shall mean the sponsored research agreement executed between Lonza and MEE with an effective date of [***], covering Lonza’s funding for the further research, development and optimization of the Ancestral
Technology at MEE under the supervision of [***] as set forth under the Research Plan of the SRA. 
 1.50 “SRA Ancestral
Technology” shall mean, collectively, any and all sequences, compositions, methods, tools, protocols or technology, and any and all viral vectors, sequences or compositions identified or created from such methods, tools, protocols or
technology, in each case solely to the extent identified, developed, generated or otherwise included or described in materials, sequences or compositions generated during and in the i performance of the SRA. 

1.51 “Sublicense” or “Sublicense Agreement” means any agreement in which a Sublicensee
receives a sublicense from TDTx or any of its Affiliates granting it commercial license rights or an option to acquire commercial license rights under the Licensed Intellectual Property or any subset thereof to discover, research, develop and/or
commercialize Licensed Products. For clarity, any M&A Transaction shall not be considered to be a Sublicense or Sublicense Agreement under this Agreement. 

1.52 “Sublicensee” means any Person which receives a Sublicense or enters into a Sublicense Agreement under
some or all of the rights granted to TDTx under this Agreement. 
 1.53 “TDTx Intellectual Property” means
any Intellectual Property (other than the Licensed Intellectual Property, MEE Intellectual Property or any Lonza Intellectual Property) owned or Controlled by TDTx, whether prior to, on or after the Effective Date. 

1.54 “Territory” means worldwide. 

1.55 “Third Party” means any Person other than Lonza, MEE, TDTx or any of their respective Affiliates. 

1.56 “Third Party License Agreement” means any agreement entered into by TDTx, or by any of its Affiliates or
by any Sublicensee with a Third Party, as applicable depending upon whether TDTx, its Affiliate or Sublicensee is the entity that will be paying royalties on Net Sales of the relevant Licensed Product(s), or any amendment or supplement thereto, in
each case after the Effective Date, whereby royalties, fees or other payments are to be made by TDTx, its Affiliates or any Sublicensee (as applicable) to such Third Party in connection with the grant of license rights under Intellectual Property
that Covers or claims either the composition of matter, manufacture or the method of treatment or use of any vector or Licensed Product or Licensed Transgene or Licensed Transgene regulatory element for the relevant Licensed Product in the Field of
Use that is Controlled by such Third Party, which rights TDTx or its Affiliates or Sublicensee, as applicable, reasonably determine are necessary to develop, manufacture, have made, import, export, use, sell, offer for sale or otherwise
commercialize the Licensed Product in the Field of Use. 
 1.57 “Ultra-Rare Field” means the Ultra-Rare Field
as such term is defined in the Amended and Restated Lonza-MEE Agreement. 
 1.58
“Valid Claim” means (a) a claim of an issued and unexpired patent, which claim has not been revoked or held unenforceable, unpatentable or invalid by an unappealed or unappealable decision of a court or other
governmental agency of competent jurisdiction and that has not been finally abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise,
or (b) a claim of a patent application that is being prosecuted in good faith and has been pending less than [***] from the date of filing of the earliest patent application from which such patent application claims priority, which claim has
not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. For clarity, in the event that any pending claim of a patent application that does not meet the criteria under
subpart (b) of this Section 1.59 subsequently becomes an issued claim that would qualify under subpart (a) of this Section 1.59, such claim, once it issues, shall thereafter be considered a Valid Claim under this definition. 

  
 9. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 2 

GRANT OF LICENSES, RESERVED RIGHTS AND SUBLICENSING 

2.1 License Grant. Subject to all of the applicable terms and conditions of this Agreement, Licensors hereby grant to TDTx an
exclusive, non-transferable (except as expressly permitted in Article 17 (“Non-Assignability”), sublicensable (through multiple tiers) right and
license, under all of Licensors’ rights (both separately and collectively) in and to the Licensed Intellectual Property (provided, however, that the Arising Patent Rights are included within the license granted under this
Section 2.1 only pursuant to the exercise of an option to such Arising Patent Rights in accordance with the provisions of Section 2.6), to discover, research, develop, make, have made, manufacture, use, sell, offer to sell, import, export,
market, promote, distribute, register and otherwise commercially exploit Licensed Products, in the Field of Use within the Territory. For clarity, pursuant to the Amended and Restated Lonza-MEE Agreement, the
license granted to TDTx under this Section 2.1 shall not be subject to any of the restrictions, obligations or limitations with respect to the scope of the licensed Field of Use that were applicable to Lonza under the Original Lonza-MEE Agreement, and shall be subject only to the terms and conditions of this Agreement. 

Notwithstanding the above license grant, solely with respect to any manufacturing process subject matter disclosed in [***], Licensors hereby
grant to TDTx a non-exclusive, non-transferable (except as expressly permitted in Article 17
(“Non-Assignability”), nonsublicensable right and license, under the manufacturing process subject matter included in [***] and applications related therefrom to discover, research,
develop, make, manufacture, use, sell, offer to sell, import, export, market, promote, distribute, register and otherwise commercially exploit Licensed Products, in the Field of Use within the Territory. For clarity, TDTx shall have the exclusive
right and license (with the right to sublicense) as described in the preceding paragraph to all non-manufacturing process subject matter, including any composition of matter, disclosed in [***] and
applications related therefrom. 
 2.2 Responsibility for Affiliates and Sublicensees. TDTx shall have the right to grant
sublicenses to its Affiliates and to its Sublicensees to cause the performance by any of its Affiliates and/or Sublicensees of some or all of TDTx’s obligations hereunder. Until such time that [***], the right of TDTx [***]. TDTx shall be
responsible and liable for any and all acts or omissions of its Affiliates or Sublicensees in connection with the exercise by such Affiliates or Sublicensees of any sublicense rights granted hereunder and their performance of any of TDTx’s
obligations hereunder. If Licensors have a claim arising under this Agreement against an Affiliate or Sublicensee, Licensors may seek a remedy directly against TDTx and may, but is not required to, seek a remedy against the Affiliate or Sublicensee.
Any termination of the Agreement under Article 11 as to TDTx also constitutes termination as to any of its Affiliates. For clarity, pursuant to the Amended and Restated Lonza-MEE Agreement, the right to grant
sublicenses as granted to TDTx under this Section 2.2 shall not be subject to any of the restrictions, obligations or limitations with respect to the scope of permitted sublicenses within the licensed Field of Use that were applicable to Lonza
under the Original Lonza-MEE Agreement, and shall be subject only to the terms and conditions of this Agreement. 

2.3 No Implied Licenses. This Agreement confers no license or rights by implication, estoppel or otherwise under any patent
applications or patents owned in whole or in part by Lanza or MEE other than the Ancestral Technology Patent Rights and the Arising Patent Rights. For the avoidance of doubt, neither TDTx, its Affiliates nor any Sublicensee shall use or practice the
Licensed Intellectual Property with respect to any Excluded Target or any Excluded Field of Use, unless and until any such rights revert back to either of the Licensors under the applicable Existing Third Party License/Sublicense Agreement, wherein
such reversion of rights to Licensors would then be automatically included in the license grant to TDTx as provided in Section 2.1. 

  
 10. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.4 Reserved Rights. The licenses granted by Licensors hereunder are subject
to the following reserved rights: 
 2.4.1 Retained Rights of MEE; Requirements. Any and all licenses granted hereunder by
Licensors are subject to: 
 (a) the retained right of MEE and MEE’s Affiliates and academic, government and not-for-profit institutions to make and to use the subject matter described and/or claimed in the Licensed Intellectual Property; provided, however, that such
making and using shall not include the production, commercialization or manufacture of products for sale and only to the extent that such making and using by academic, government and
not-for-profit institutions does not conflict with any of the provisions of this Agreement; and 

(b) for Licensed Intellectual Property supported by federal funding, the rights, conditions and limitations imposed by U.S. law (see
35 U.S.C. § 202 et seq. and regulations pertaining thereto), including without limitation: 
 (i) the royalty-free non-exclusive license granted to the U.S. government; and 
 (ii) the requirement that any
Licensed Products used or sold in the United States shall be manufactured substantially in the United States. 
 2.4.2 Upon the
written request of TDTx, such request to be provided in each case within [***] after the end of a Calendar Quarter, MEE shall have a period of at least [***] to provide TDTx with the name(s) of the applicable academic, governmental or not-for-profit organizations to which MEE has entered into any written agreement granting any rights under the Licensed Intellectual Property in connection with the rights
retained by MEE pursuant to Section 2.4.1 and a general description of the research being conducted by such organizations, all such information to be provided to TDTx subject to the confidentiality obligations of such written agreement between
MEE and such academic, governmental or not-for-profit organization. 

2.4.3 Technology Transfer. MEE (through [***] or his designee) shall use reasonable efforts to disclose and transfer to TDTx,
under the confidentiality obligations of this Agreement, within [***] after the Effective Date of this Agreement, the Ancestral Technology Know-How that is listed on Schedule E as of the Effective Date. In
addition, within [***] after the Effective Date, MEE will provide to TDTx an identification of further Ancestral Technology Know-How resulting from the SRA, and the Parties will agree on an amendment to
Schedule E to incorporate such further Ancestral Technology Know-How. Upon such amendment, MEE (through [***] or his designee) will use reasonable efforts to disclose and transfer to TDTx such further
Ancestral Technology Know-How, under the confidentiality obligations of this Agreement, within [***]. 

2.5 Sublicensing. 

2.5.1 Right to Grant Sublicenses. Subject to the terms and conditions of this Agreement, TDTx shall have the right to sublicense
its rights under the Agreement, in whole or in part, to one or more Third Parties, and to one or more TDTx Affiliates, subject always to the requirements of Section 2.5.2 regarding the content of all such Sublicenses. TDTx (and its Affiliates)
may permit any of its Sublicensees to grant further sublicenses to Third Parties, including through multiple tiers, under their rights to the Licensed Intellectual Property; provided, however, that each such Sublicense through each
tier shall be subject to and shall comply with the requirements of Section 2.5.2. TDTx shall be responsible for any breach of a Sublicense by a Sublicensee that results in a material breach of this Agreement. 

  
 11. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.5.2 Content of Sublicenses. Each Sublicense granted hereunder shall be
consistent with the terms and conditions of this Agreement, excluding [***], and will include but not be limited to, in the same or substantially the same form, the provisions of [***] of this Agreement, shall incorporate terms and conditions
sufficient to enable TDTx to comply with this Agreement, shall allow further Sublicenses by a Sublicensee through multiple tiers, in each case (and for each tier) only on terms that are consistent with the requirements of this Section 2.5.2,
and shall provide that MEE and Lonza are each third party beneficiaries thereof. Upon termination of this Agreement or any Sublicense granted hereunder for any reason, any Sublicenses shall be addressed in accordance with the terms and conditions of
Section 11.5.7 (Sublicense Survival). Any Sublicense which is not in accordance with the requirements of this Section 2.5.2 shall be null and void. 

2.5.3 Copies of Sublicenses to Licensors. TDTx shall deliver or cause to be delivered to Licensors a copy of any and all [***]
Sublicenses and any amendments thereto, including all exhibits, attachments and related documents thereto, (which copy may be redacted only to remove specific technical or scientific information pertaining to sensitive proprietary technology or
information of a Sublicensee which are not necessary to monitor compliance with this Agreement, but may not be redacted to remove any of the financial terms of the Sublicense) within [***] after execution by TDTx or its Affiliate, as applicable, and
the relevant Sublicensee. TDTx shall also provide Licensors [***] with a copy of the reports received by TDTx or its Affiliate, as applicable, from its Sublicensees during the preceding [***] period, beginning [***] from the effective date of the
sublicense agreement, to the extent such reports are related to (1) TDTx’s compliance with its obligations under Section 6.1 of this Agreement and (2) TDTx’s financial obligations under Article 3 of this Agreement. 

2.5.4 TDTx’s Continuing Obligations. Nothing in Section 2.5 may be construed to relieve TDTx of its obligations to
Licensors under this Agreement, including but not limited to TDTx’s obligations under Section 6.1. 
 2.6 Option to
License Arising Patent Rights after the Effective Date. During the Term, TDTx shall have the exclusive option to obtain an exclusive license, on behalf of itself and its Affiliates, in the Field of Use to any Arising Patent Rights which Lonza or
MEE owns or Control prior to or after the Effective Date according to the following terms: 
 2.6.1 At any time prior to or after the
Effective Date, if either of the Licensors obtain ownership or Control of any Arising Patent Rights, Licensors shall notify TDTx in writing of such Arising Patent Rights and shall provide TDTx with a description of such Arising Patent Rights. If
Lonza’s ownership or Control of such Arising Patent Rights is the result of Lonza or its Affiliates having acquired or exercised its option rights under the SRA in any Intellectual Property that is subject to a license, sublicense, or other
agreement between Lonza and/or its Affiliates and MEE, it shall automatically be deemed Licensed Intellectual Property and included in the license granted under Section 2.1. If MEE’s ownership or Control of any Arising Patent Rights is not
subject to a license, sublicense, or other agreement between Lonza and/or its Affiliates and MEE either [***], MEE will notify TDTx of such Arising Patent Rights and TDTx shall have [***] from its receipt of such notice to decide whether it wishes
to obtain a license to the Arising Patent Rights (the “Evaluation Period”). If TDTx notifies MEE within the Evaluation Period that it wishes to acquire an exclusive license to the Arising Patent Rights in the Field of Use in
accordance with and subject to all of the terms and conditions set forth in this Agreement, upon payment of reasonable compensation (the “License Fee”) paid to MEE, as negotiated in good faith by MEE and TDTx, TDTx shall have
a license to such Arising Patent Rights and such Arising Patent Rights shall be deemed included as Licensed Intellectual Property under Section 2.1 of this Agreement. Prior to the expiration of the Evaluation Period (or such earlier time as
TDTx may notify Lonza in writing of its decision to not include such Arising Patent Rights within the scope of this Agreement), MEE shall not grant any licenses under or to such Arising Patent Rights in the Field of Use to any Third Party. 

  
 12. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.6.2 In the event that any Arising Patent Rights are added to the exclusive license
granted to TDTx under Section 2.1 by operation of the provisions of Section 2.6.1, the following terms and conditions shall apply with respect to the respective rights of MEE, Lonza and TDTx under the SRA: 

(a) The retained rights of MEE with respect to any such included Arising Patent Rights shall be as described and defined in
Section 2.4.1 of this Agreement, and not as the MEE Retained Rights are defined and described in the SRA; and 
 (b) Licensors
hereby grant to TDTx a fully-paid and royalty-free, non-exclusive, non-transferable (except in accordance with Article 17) and
non-sublicenseable (except to its Affiliates) license to use the SRA Process Intellectual Property solely for limited internal research or evaluation purposes only for Licensed Products, in the Field of Use
within the Territory but not for any development or commercial use. 
 2.6.3 For clarity, the
Know-How relating to the SRA Ancestral Technology shall be deemed to be included within the Licensed Intellectual Property as part of the Ancestral Technology Know-How
as of the Effective Date under the exclusive license granted to TDTx under Section 2.1 without any requirement for the exercise of any option rights under the SRA by either Lonza or by TDTx, it being understood that the exercise of option
rights under the SRA pursuant to Section 2.6.1 shall be required only for the Arising Patent Rights, and not for such Know-How relating to the SRA Ancestral Technology. The Parties shall describe any new
Arising Patent Rights that arise after the Effective Date and are licensed hereunder at any time during the Term in the form of updates to Schedule A and within [***] of the Effective Date for updates to Schedule E as set forth in
Section 2.4.3, which updated Schedule A and/or E shall replace any prior version(s) thereof when signed by the Parties; provided that failure to update such Schedule A shall not affect the rights granted to TDTx under this
Section 2.6. In the event TDTx does not exercise its rights to any Arising Patent Rights of which it has been notified by MEE under this Section 2.6 prior to the end of the applicable Evaluation Period, MEE shall be free to grant licenses
under and to such Arising Patent Rights in the Field of Use to any Third Party, subject to TDTx’s and its Affiliates’ existing rights in the Licensed Intellectual Property granted under this Agreement. 

2.7 MEE’s Ophthalmology Target Option. 

ln the event that an investigator at MEE or at any of its Affiliates is pursuing an ongoing active research program with respect to any
transgene or biological target within the “Ophthalmology Field”, which shall be defined as [***], wherein such ongoing research program has received at least [***] in aggregate total funding (excluding indirect costs) from
MEE or from Third Party grant sources (a “Qualifying MEE Ophthalmology Program”), and MEE desires to obtain a commercial sublicense from TDTx under any of the Licensed Intellectual Property with respect to such transgene or
biological target in the Ophthalmology Field, the following terms and conditions shall apply. For clarity, neither MEE (nor any of its Affiliates or any Third Party) shall be able to invoke the option rights of MEE under this Section 2.7 in the
absence of such a Qualifying MEE Ophthalmology Program. 
 (a) MEE will notify TDTx at the JSC of its interest in obtaining a
commercial sublicense under the relevant Licensed Intellectual Property for such transgene or biological target in the Ophthalmology Field, and then, unless TDTx can demonstrate at the JSC that such transgene or biological target is not an Available
Target (in which case MEE shall have no right to obtain a commercial sublicense under the Licensed Intellectual Property for any transgene or biological target that is not an Available Target at the time of request by MEE at the JSC), the following
process shall apply; 
 (b) If the transgene or biological target is an Available Target at the time of request by MEE at the JSC,
TDTx shall have a period of [***] for TDTx to decide whether it wishes to pursue a collaboration with MEE for the research, development and commercialization of any Licensed Products directed to such Available Target in the Ophthalmology Field; 

(c) If TDTx notifies MEE in writing during such [***] period that it desires to pursue such a collaboration with MEE, MEE and TDTx
shall enter into good faith negotiations for a definitive collaboration agreement with respect to the relevant transgene or biological target in the Ophthalmology Field; 

  
 13. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) If TDTx does not notify MEE during such [***] period that it desires to pursue
such a collaboration with MEE, or if it does notify MEE during such [***] period of its interest in pursuing such a collaboration but MEE and TDTx are not able to consummate a definitive collaboration agreement after good faith negotiations, TDTx
shall grant a commercial sublicense to MEE or shall grant a Sublicense directly to MEE’s proposed Third Party Sublicensee, the recipient of such commercial Sublicense to be determined at the sole discretion of MEE, under the relevant Licensed
Intellectual Property for the relevant transgene or biological target solely in the Ophthalmology Field. If such commercial sublicense is between MEE and TDTx, then the commercial sublicense shall be sublicenseable by MEE to MEE’s proposed
Third Party Sublicensee. A commercial sublicense granted to either MEE or a Sublicense granted by TDTx to MEE’s proposed Third Party Sublicensee shall be subject to all of the terms and conditions of this Agreement applicable to Sublicenses
granted by TDTx, including, without limitation, the provisions on Sublicense Income as set forth in Section 3.7, and will be granted on financial terms and conditions to be negotiated by TDTx and MEE or MEE’s proposed Third Party
Sublicensee in good faith having considered the commercially reasonable, risk-adjusted fair market value of such Licensed Intellectual Property at the time of such commercial sublicense or Sublicense, as applicable. For clarity, if MEE’s
proposed Third Party Sublicensee enters into a Sublicense thereunder with TDTx, any and all license payments, including upfront license payments, annual maintenance payments and milestone and royalty payments due for such Sublicense will be owed by
MEE’s proposed Third Party Sublicensee, and not by MEE. For further clarity, if the commercial sublicense in the Ophthalmology Field is between TDTx and MEE and there is a subsequent related commercial sublicense thereunder directly between MEE
and MEE’s proposed Third Party Sublicensee in the Ophthalmology Field, any such license payments, to the extent such license payments are attributable to the Licensed Intellectual Property licensed to TDTx hereunder and not to any other
Intellectual Property of MEE, including upfront license payments, annual license maintenance payments and milestone and royalty payments, received by MEE from such commercial Sublicensee shall be paid to TDTx by MEE. In the event of any termination
of any such Sublicense granted to MEE’s proposed Third Party Sublicensee under the provisions of this Section 2.7, all rights to the relevant Licensed Intellectual Property for the relevant transgene or biological target in the
Ophthalmology Field shall revert fully to TDTx, at no additional cost to TDTx; provided, however, that MEE shall retain all of its rights to any new intellectual property generated by MEE in the course of conducting the Qualifying MEE
Ophthalmology Program, excluding the Licensed Intellectual Property. 
 ARTICLE 3 

FINANCIAL TERMS 
 As the
sole monetary consideration for the rights granted by Licensors under this Agreement, TDTx shall make the following payments to Licensors according to this Article 3. As additional consideration for such rights, TDTx shall issue certain shares of
TDTx’s common stock in accordance with Section 3.1. 
 3.1 Equity. 

3.1.1 On the Effective Date, TDTx shall issue, pursuant to a Stock Issuance Agreement between TDTx and Lonza (the “TDTx-Lonza Stock Issuance Agreement”) a total number of shares of common stock of TDTx, $0.001 par value per share [***] of TDTx’s issued and outstanding common stock calculated on a Fully-Diluted
Basis after giving effect to such issuance, (the “Lonza Shares”) in the name of Lonza. On the Effective Date, TDTx shall issue, pursuant to a Stock Issuance Agreement between TDTx and MEE (the “TDTx-MEE Stock Issuance Agreement”) a total number of shares of common stock of TDTx, $0.001 par value per share equivalent to [***] of TDTx’s issued and outstanding common stock calculated on a
Fully-Diluted Basis after giving effect to such issuance, (the “MEE Shares”), in the name of MEE. TDTx represents to Licensors that, immediately following the Effective Date, the aggregate number of Lonza Shares and MEE
Shares (the Lonza Shares and MEE Shares collectively referred to as the “Shares”) equals [***] of TDTx’s issued and outstanding common stock calculated on a Fully-Diluted Basis after giving effect to such issuances. For
purposes of this Section 3.1, “Fully-Diluted Basis” shall mean that the total number of issued and outstanding shares of the DTx’s capital stock, which shall be calculated to include conversion of all issued and
outstanding securities then convertible into capital stock, the exercise of all then outstanding options and warrants to purchase shares of capital stock, whether or not then exercisable, and shall assume the issuance or grant of all securities
reserved for issuance pursuant to any TDTx stock or stock option plan in effect on the date of the calculation. In addition, on the Effective Date, TDTx, Lonza, MEE and certain other holders of common stock of TDTx shall enter into Shareholder
Agreement (the “Shareholder Agreement”). 

  
 14. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.1.2 Partners Innovation Fund and Lonza Purchase Right. Beginning on the
Effective Date, MEE, through Partners Innovation Fund, LLC (“PIF”) and Lonza, shall each have the right, but not the obligation, to purchase up to MEE’s and Lonza’s respective Share of the securities issued in any
Qualifying Offer on the terms and conditions set forth in this Section 3.1.2 (“Purchase Right”). 
 (a)
Exercise of Purchase Right. Within a reasonable period of time immediately following the receipt of a Qualifying Offer, TDTx shall, in accordance with Article 14 of this Agreement, provide written notice to PIF and Lonza of any such
Qualifying Offer. PIF and Lonza will both then have [***] to exercise their Purchase Right either in whole or in part by providing written notice to TDTx (“Exercise Period”). PIF and Lonza shall then have [***] following
TDTx’s receipt of PIF’s and/or Lonza’s written notice to exercise the Purchase Right to negotiate an investor rights agreement with TDTx (“Purchase Period”). 

(b) Termination of Purchase Right. The Purchase Right shall terminate upon the earliest to occur of the following (each a
“Termination Event”): 
 (i) PIF’s or Lonza’s execution of an investor rights agreement or similar
agreement in connection with a Threshold Offer; 
 (ii) PIF and/or Lonza fails to give notice of its desire to exercise the Purchase
Right during the Exercise Period for a Qualifying Offer which has its final closing within [***] of the date such notice was received by PIF and Lonza and which is closed on terms that are the same or less favorable to the investors than the terms
contained within the notice given by TDTx to PIF and Lonza in accordance with Section 3.1.2(a); 
 (iii) The closing of a firm
commitment underwritten public offering of TDTx’s common stock; or 
 (iv) The closing of the sale of all or substantially all
of TDTx’s assets to a company publicly traded on one of the Major Recognized Exchanges. 
 (c) Definitions. The
following terms shall have the definitions ascribed to them under this Section for the purposes of interpreting Sections 3.1.2(a) and 3.1.2(b). 

(i) “Adjustment Event” means the final closing of the first Threshold Offer occurring after the Effective Date
of this Agreement. 
 (ii) “Fully-Diluted Basis” means all of TDTx’s capital stock either outstanding
or reserved for issuance, assuming the exercise of all options, warrants and other convertible securities and the conversion of all preferred stock and convertible debt instruments and assuming the grant of all shares reserved under any equity
incentive or similar plans. 
 (iii) “Major Recognized Exchange” shall mean the New York Stock Exchange, the
NASDAQ, or any comparable stock exchange reasonably acceptable to the holders of registrable securities. 

  
 15. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (iv) “Qualifying Offer” means a private offering of the
TDTx’s equity securities (or securities convertible into or exercisable for the TDTx’s equity securities) for cash (or in satisfaction of debt issued for cash) having its final closing on or after the Effective Date of this Agreement and
which includes investment by one or more [***] other than PIF and Lonza. 
 (v) “Share” means: 

(A) [***] with respect to any Qualifying Offer having a closing on or before the date of an Adjustment Event; or 

(B) (B) with respect to any Qualifying Offer having a closing after an Adjustment Event, but before a Termination Event, the
percentage necessary for PIF and Lonza to maintain its pro rata ownership interest in the TDTx on a Fully-Diluted Basis. 
 (vi)
“Threshold Offer” means any Qualifying Offer which either: (x) is at least [***] in size or (y) involves the sale to outside investors of at least [***] of the equity securities outstanding after such round on a
Fully-Diluted Basis. 
 With regard to each Qualifying Offer, the number of securities that may be purchased by PIF pursuant to this
Section 3.1.2 shall be reduced by the number of such securities purchased by PIF (or MEE, or delegee, successor, assignee, beneficial interest holder or Affiliate (as defined in the Shareholder Agreement, as may be amended from time to time) of
PIF or MEE) pursuant to the pre-emptive right under the Shareholder Agreement, and the number of securities that may be purchased by Loma pursuant to this Section 3.1.2 shall be reduced by the number of
such securities purchased by Lonza (or its delegee, successor, assignee, beneficial interest holder or Affiliate (as defined in the Shareholder Agreement) pursuant to the pre-emptive right under the
Shareholder Agreement. 
 3.2 Milestone Payments. 

(a) With respect to at least one (1) Licensed Product directed to a named biological target or transgene pursued within the Field
of Use , TDTx or its Affiliate or Sublicensee, as applicable, shall make the development and sales milestone payments in the amounts corresponding to the achievement by either TDTx or any of its Affiliates, or its Sublicensees of the development and
sales milestones set forth on Schedule B. Within [***] after achievement of any such milestone event by TDTx or any of its Affiliates or Sublicensees or within [***] after receiving notice from any of its Sublicensees that any such sales or
development milestone event has been achieved, as the case may be, TDTx shall notify Licensors of such achievement in writing and Licensors shall issue TDTx an invoice for the amount of the corresponding milestone payment, which invoice TDTx shall
pay or cause to be paid within [***] following its receipt thereof if such milestone was achieved by TDTx, and within [***] after TDTx’s receipt of payment from its Affiliate or from its Sublicensee if such milestone was achieved by its
Affiliate or Sublicensee, as applicable. 
 (b) For Sublicensees, each milestone payment set forth on Schedule B shall be payable
for [***] Licensed Product per named biological target or transgene that is pursued within the Field of Use, for [***] Licensed Product to achieve the milestone event, and [***] directed to the same named biological target or transgene unless [***],
it being understood and agreed by the Parties that [***]. 
 (c) For TDTx or its Affiliate, each milestone payment set forth on
Schedule B shall be payable for only one (1) Licensed Product per named biological target or transgene that is pursued within the Field of Use by TDTx or its Affiliate, for only the first Licensed Product to achieve the milestone event, and
[***] directed to the same named biological target or transgene; provided, however, that if TDTx or its Affiliate is able to achieve the [***] shown in Schedule B for a second Licensed Product directed to the same named biological
target or transgene, then TDTx or its Affiliate (as applicable) shall be required to pay the milestone amount shown on Schedule B for such second Licensed Product for the [***] and shall be obligated to pay retroactively all prior milestone event
payments shown in Schedule B for any such second Licensed Product directed to the same named biological target or transgene. 

  
 16. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) For clarity, if a first Licensed Product progressed by either TDTx, its
Affiliate or by a Sublicensee for a given named biological target or transgene fails and is no longer progressed, and is replaced with a second Licensed Product that is directed to the same named biological target or transgene, the milestone amounts
shown in Schedule B will only be payable for the second Licensed Product for the milestone events that were not yet achieved by the first Licensed Product. Also for clarity, a Licensed Product will not be considered to be a second or different
Licensed Product under this Section 3.2 relative to any first or other Licensed Product merely due to [***]. As used herein [***]. 

3.3 Royalties. 

3.3.1 Licensed Products Commercialized by TDTx. In further consideration of the license granted to TDTx in this Agreement and
subject to Sections 3.3.3, 3.4 and 3.5, TDTx shall pay to Licensors, during each applicable Royalty Term, royalties at the applicable royalty rates set forth in Schedule C, based on the portion of annual worldwide Net Sales within each of the
royalty tiers set forth in such Schedule C. For the avoidance of doubt, such royalties shall be payable in respect of annual worldwide Net Sales of each Licensed Product only for such Net Sales made and recorded by TDTx or its Affiliates. In
addition, in no event shall [***]. 
 3.3.2 Licensed Products Commercialized by a Sublicensee. In further consideration of the
license granted to TDTx in this Agreement and subject to Sections 3.3.3, 3.4 and 3.5, TDTx shall pay to Licensors, during each applicable Royalty Term, a portion of the royalty income payments received from a Sublicensee, such royalty income
payments based on the applicable royalty sharing rates set forth in Schedule D for the Sublicensee royalty income payment. For the avoidance of doubt, such royalty payments shall be payable in respect of annual worldwide Net Sales of each Licensed
Product only for such Net Sales made and recorded by Sublicensees. In addition, [***]. 
 3.3.3 Royalty Reductions. The
royalties payable to Licensors hereunder shall be subject to the following reductions set forth in paragraphs (a) through (c) of this Section 3.3.3, which shall apply in addition to the royalty offsets as described in Section 3.4:

 (a) Non-Valid Claim Covered Licensed Products during Royalty Term. If the [***] of
a Licensed Product is not Covered by a Valid Claim in the country of [***] and at the time of [***] (either because no Valid Claim within the Ancestral Technology Patent Rights ever existed Covering such Licensed Product in the relevant country or
the Valid Claim within the Ancestral Technology Patent Rights no longer exists), but the [***] of the Licensed Product occurs within the Royalty Term in the relevant country, then, in respect of Net Sales in such country, the royalties payable on
the annual Net Sales of such Licensed Products sold in such country by TDTx, its Affiliates and Sublicensees during such period of the Royalty Term shall be calculated at rates that are reduced [***] from the amounts set forth in Schedule C. 

(b) Compulsory Licenses. In the event that Lonza, MEE or TDTx receives a request for a Compulsory License anywhere in the
world, it shall promptly notify the other Parties. If any Third Party obtains a Compulsory License in any country, then Lonza, MEE or TDTx (whoever has first notice) shall promptly notify the other Parties. For the purposes of calculating the
royalties due to Licensors under Section 3.3 with respect to Net Sales of any Licensed Product in such country where a Compulsory License has been granted, the royalty rate payable by TDTx hereunder for Net Sales of any Licensed Product in such
country will be adjusted to [***]. In the event any Third Party is granted a sublicense of the rights under Section 2.1 by TDTx in order to avoid the imposition of a Compulsory License (such Third Party, a “Compulsory
Sublicensee”), where the royalty rate payable by such Compulsory Sublicensee on Net Sales of Licensed Products is less than the royalty rate paid by TDTx’s other Sublicensee(s) on the Net Sales of Licensed Products, then the
royalty rate payable by TDTx to Licensors hereunder for Net Sales the of Licensed Product by the Compulsory Sublicensee shall be reduced [***]. For example, [***]. 

  
 17. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (c) Generic Competition. Royalties payable on Net Sales of Licensed Products
in any given country shall be, on a Licensed Product by Licensed Product basis, subject to additional reductions of (i) [***] following a decrease in Net Sales of at least [***] and (ii) [***] following a decrease in Net Sales of [***]; in each
case, where such decrease in Net Sales is [***] to entry of one or more “generic” or “biosimilar” product(s) (as applicable) in such country in a particular Calendar Quarter compared to the average Net Sales of such Licensed
Product in such country over the [***] entry of such generic or biosimilar product. 
 3.4 Offsets from Royalty Payments; Minimum
Royalty Rates. 
 3.4.1 Third Party Intellectual Property. If TDTx and/or any of its Affiliates, or Sublicensees enter
into one or more Third Party License Agreements that TDTx or its Affiliate or Sublicensee, as applicable, reasonably determines is [***] for TDTx or any of its Affiliates, or Sublicensees to develop, make, use, import, or sell the relevant Licensed
Product, TDTx or its Affiliate or Sublicensee, as applicable, will have the right to offset [***], against the royalty payments due to Licensors with respect to the annual Net Sales of such Licensed Product in such country, subject to the minimum
royalty rate requirements of Sections 3.4.2 and 3.4.3, as applicable. 
 3.4.2 Notwithstanding the right of TDTx and its Affiliates
to apply in a cumulative manner the royalty rate reductions and offset rights as described in Section 3.3.3 and Section 3.4.1, in no event shall the final adjusted royalty rate due to Licensors on the basis of annual Net Sales of Licensed
Products by TDTx or its Affiliates as shown in Schedule C be reduced [***] for any given Calendar Quarter, provided, however, that TDTx or its Affiliate shall have the right to carry forward any such offsets or reductions that would
result in the royalty rate being reduced [***] in any given Calendar Quarter for any Licensed Product into subsequent Calendar Quarters, [***]. 

3.4.3 Notwithstanding the right of Sublicensees of TDTx or Sublicensees of its Affiliates to apply in a cumulative manner the royalty
rate reductions and offset rights as described in Section 3.3.3 and Section 3.4.1, in no event shall the final adjusted royalty rate owed by any Sublicensees of TDTx or Sublicensees of its Affiliates under any Sublicense Agreement on the
basis of annual Net Sales of Licensed Products by such Sublicensee be less than [***] without the application of any of the reductions or offsets described in Section 3.3.3 or Section 3.4.1, and in no event shall such final adjusted
royalty rate owed [***] after the cumulative application of all applicable reductions and offsets described in Section 3.3.3 and Section 3.4.1; provided, however, that [***] Covering the Licensed Product in the relevant
country at the time of [***] of the Licensed Product. Sublicensees shall have the right to carry forward any such offsets or reductions that would result in the royalty rate being reduced to an amount less than the minimum required royalty rate in
any given Calendar Quarter for any Licensed Product into subsequent Calendar Quarters, [***]. In addition, in cases where the minimum royalty rate requirement under this Section 3.4.3 is applicable, TDTx or its Affiliate shall have the right to
[***] an exception to the minimum royalty rate requirement under this section based upon the grounds that the minimum royalty rate requirement would result in [***], and if [***], such exception to the minimum royalty rate requirement shall be
[***]. For clarity, regardless of the final adjusted royalty rate that applies to a Sublicensee under a Sublicense Agreement, the Royalty Income Sharing percentages as shown in Schedule D shall apply to all royalty income received by TDTx or its
Affiliates for the annual Net Sales of Licensed Products by all Sublicensees of TDTx or Sublicensees of its Affiliates. 
 3.5 [Reserved]

 3.6 Payment. TDTx shall pay such royalties due to Licensors under this Agreement within [***] after the last day of
each Calendar Quarter in which such royalty payments are owed, by [***]. 
 3.7 Sublicense Income. 

3.7.1 Sublicense Income Payments. Except as set forth in Section 3.7.2, and subject to the reductions as described in
Section 3.8 and the exclusions described in Section 3.7.3, TDTx shall pay Licensors a percentage of all types of payments and consideration ([***]) TDTx or any of its Affiliates receives under a Sublicense Agreement from a Sublicensee,
including but not limited to [***] (collectively, the “Sublicense Income”) in the applicable percentage payment as set forth below (each such percentage payment of Sublicense Income is referred to as a “Sublicense
Income payment” and each such percentage reduction to be applicable for a Sublicense Income Payment is referred to as a “Step-Down”): 

(a) [***] of Sublicense Income attributable to all Licensed Products received under a Sublicense Agreement entered into after [***]
and prior to [***]; 

  
 18. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) A Step-Down to [***] of the Sublicense Income attributable to all Licensed
Products received under a Sublicense Agreement entered into on or after [***] and prior to [***], whichever occurs first; 
 (c) A
Step-Down to [***] of the Sublicense Income attributable to all License Products received under a Sublicense Agreement entered into after [***] and prior to [***]; and 

(d) A Step-Down to [***] of Sublicense Income attributable to all Licensed Products received under a Sublicense Agreement entered into
on or after [***]. 
 For clarity, a Step-Down is [***], and the Step-Downs will [***]. For further clarity, each Sublicense Agreement will
[***] and the applicable Step-Down will be applied [***]. 
 3.7.2 Greater of Sublicense Income Payments Payable to Licensors.
Without limiting TDTx’s rights under Section 3.7.4, where the Sublicense Income Payment corresponds to the achievement of one of the same (or [***]) development and/or sales milestone events as those listed in Schedule B, TDTx shall
pay to Licensors the greater of the amount associated with such milestone in Schedule B or the payment amount due after applying the applicable percentage under Section 3.7.1 to the Sublicense Income received from a Sublicensee in connection
with the achievement of such milestone event. 
 3.7.3 Exclusions. Excluded from Sublicense Income with respect to which TDTx
must pay such percentage pursuant to Section 3.7.1 or 3.7.2, as applicable, are [***]. 
 3.7.4 No Double Payment.
Notwithstanding anything to the contrary in Section 3.7, TDTx shall be entitled to (i) deduct from any Sublicense Income Payment due to Licensors the amount of [***], and (ii) deduct from any Sublicense Income Payment due to Licensors
the amount of [***]; provided, however, that in both (i) and (ii) any amount paid to Licensors pursuant to Section 3.2 may be deducted from Sublicense Income Payments received from any Sublicensee only once. 

3.7.5 Apportionment for Broader Transactions involving Third Party IP. In the event that a Sublicense is part of a broader
transaction (other than an M&A Transaction) that involves, in addition to the grant of a Sublicense under the Ancestral Technology Patent Rights, the grant of license or option rights or other rights to other assets, programs or intellectual
property that were obtained or licensed by TDTx or its Affiliate from any Third Party, TDTx will have the right to apply a fair apportionment to [***] under any such broader transaction [***] to the value of the rights being sublicensed from
Licensors hereunder relative to the value of the other rights, assets, programs or intellectual property licensed or obtained from a Third Party that are part of such broader transaction other than the Ancestral Technology Intellectual Property;
provided, however, that (a) the right of apportionment under this Section 3.7.5 shall [***], and (b) TDTx shall [***], and (c) the [***] shall be [***], and (d) the [***]. 

3.8 Reduction of Sublicense Income Fees Payable to Licensors during [***]. Notwithstanding anything to the contrary under
this Article 3, TDTx shall be entitled to (i) during [***], permanently retain [***] of the Sublicense Income Payments that would otherwise be due to Licensors; and (ii) during [***], permanently retain [***] of the Sublicense Income
Payments that would otherwise be due to Licensors. Following the expiration of the [***] and continuing for the remainder of the Term, notwithstanding any reductions in the Sublicense Income Payment provided for under this Section 3.8, TDTx
shall pay to Licensors [***] of the Sublicense Income Payments due for any Sublicense Income received by TDTx after the expiration of [***], as applicable under the provisions of Section 3.7. 

  
 19. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.9 Patent Expenses. TDTx shall be responsible to reimburse MEE for [***] of
the patent expenses for any Licensed Product incurred and paid by MEE for the Ancestral Technology Patent Rights after the Effective Date of the Agreement, to the extent such portion of those expenses is not required to be reimbursed by a Third
Party; provided, however, that with respect to the patent expenses incurred by MEE after the Effective Date for all other Ancestral Technology Patent Rights, TDTx shall be responsible for [***] of such expenses with the remaining [***]
being paid by Existing Third Party Licensees/Sublicensees; provided however that should TDTx obtain license rights that currently reside with an Existing Third Party Licensee/Sublicensee, then TDTx shall be responsible for the relevant
additional expenses associated with the obtained license rights, and such [***] allocation to TDTx shall be adjusted upwards accordingly to account for the proportional reduction in share by the termination of the relevant Existing Third Party
License/Sublicense. TDTx shall have the right to defer its obligations under this Section 3.9 to make any such reimbursement payments until the date that TDTx raises a total of at least [***] in Capital Funding in satisfaction of the
requirements of Section 6.2.2, which within [***] upon receiving the Capital Funding, TDTx shall provide written notice to MEE. TDTx shall pay the amounts due for reimbursement commencing on the date that such [***] requirement in Capital
Funding is achieved, and MEE shall submit invoices to TDTx for TDTx’s share of such patent expenses not later than [***] after the date that such [***] requirement in Capital Funding is achieved and then on a [***] basis thereafter for future
patent expenses. Each such invoice shall include a reasonably detailed description of the expenses. TDTx shall pay amounts shown on such invoices within [***] after TDTx’s receipt of the invoice. 

3.10 Waiver or Deferral. Waiver or deferral by Licensors of any payment owed under Section 3.2 or Section 3.3 may not
be construed as a waiver or deferral of any subsequent payment owed by TDTx to Licensors. 
 3.11 Form of Payments and Taxes.

 3.11.1 Payments to Lonza. Payments may be paid by check or made by wire transfer using the following information: 

Lonza Sales AG. 
 UBS Switzerland
AG, POF Box 450, CH-8098 
 Zuerich, Switzerland [***] 

For Wires and EFT payments, please email remittance advice to [***]. 

3.11.2 Payments to MEE. Payments may be paid by check made payable to MEE and sent to: 

Massachusetts Eye and Ear Infirmary BOA-Lockbox Services 

[***] 
 or such other addresses which MEE may
designate in writing from time to time. Checks are to be made payable to “Massachusetts Eye and Ear Infirmary”. Payments may instead be made by wire transfer using the following information: 

[***] 
 TDTx shall pay all amounts
payable to Licensors under this Agreement in United States funds without deduction for taxes, exchange, collection or other charges that may be imposed by any country or political subdivision with respect to any amounts payable to Licensors under
this Agreement. TDTx is responsible for paying, or ensuring payment of, such taxes, exchange, collection or other charges, other than taxes attributable to Lanza or MEE’s net income. 

  
 20. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.12 Currency Conversion. If any currency conversion is required in connection
with any payment owed to Licensors, the conversion will be made at the buying rate for the transfer of such other currency as quoted by [***] in the case of any payment payable with respect to a specified accounting period or, in the case of any
other payment, the last business day before the date the payment is due. 
 3.13 Interest. Any payment owed to Licensors under
this Agreement that is not made when due will accrue interest beginning on the first day following the due date specified in Article 3. The interest will be calculated at the [***] rate of the sum of [***]. However, the annual rate may not exceed
the maximum legal interest rate allowed in Massachusetts. The payment of interest as required by this Section 3.13 does not foreclose Licensors from exercising any other rights or remedies they have as a consequence of the lateness of any
payment. 
 3.14 Right to Offset. Without limiting its rights under Section 11.3, TDTx shall have the right to offset any
amount owed to it by Licensors under or in connection with this Agreement, including in connection with any breach, against any future payments owed by TDTx to Licensors under this Agreement, in each case based on a final determination by an
arbitrator pursuant to an arbitration proceeding administered pursuant to Section 15.2. Such offsets shall be in addition to any other rights or remedies available under this Agreement and applicable law; provided, however, that,
[***]. In the event that TDTx is not able to deduct the full amount of the permitted deduction from the amount due to Licensors as a result of the proviso set forth in the preceding sentence, TDTx shall be entitled to deduct any undeducted excess
amount from subsequent amounts owed to Licensors (subject in each case to the proviso set forth in the preceding sentence). 
 ARTICLE 4

 ROYALTY REPORTS, PAYMENTS AND FINANCIAL RECORDS 

4.1 Royalty Reports. Within [***] after March 31, June 30, September 30 and December 31, of each year in
which this Agreement is in effect following First Commercial Sale of a Licensed Product in any country, TDTx shall deliver to Licensors full, true and accurate reports of its activities and those of its Affiliates, or Sublicensee(s), if any,
relating to the sale of Licensed Products and any Sublicense Income received during the preceding three (3) month period (each such three (3) month period, a “Calendar Quarter”). These reports must include the
following with respect to the preceding Calendar Quarter: 
 (a) Number of Licensed Products sold by TDTx, and any Affiliates, or
Sublicensees, in the Territory; 
 (b) Total revenues recorded for the Licensed Products sold by TDTx and any Affiliates, or
Sublicensees; 
 (c) Deductions applicable to determining Net Sales; 

(d) The nature and amount of Sublicense Income received by TDTx, its Affiliates or Sublicensees; and 

(e) Total royalties due to Licensors. 

With each report, TDTx shall pay to Licensors the royalties accrued during the preceding Calendar Quarter. If no royalties are due, TDTx shall
so report. If multiple Licensed Products are Covered by the license granted under this Agreement, TDTx shall separately identify Net Sales of each Licensed Product in the section of the royalty report responsive to clause (b) above. 

  
 21. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.2 Record Keeping. 

4.2.1 Books and Records. TDTx shall keep, and shall require its Affiliates, and Sublicensees to keep, true books of account
containing an accurate record (together with supporting documentation) of all data necessary for determining the amounts payable to Licensors for a period of [***] following the end of the calendar year to which they pertain. TDTx shall keep it
records at its principal place of business or the principal place of business of the appropriate division of TDTx to which this Agreement relates and shall require its Affiliates and Sublicenses to keep their books and records in the same manner.

 4.2.2 Inspections. In order for Licensors to determine the correctness of any report or payment made under this Agreement,
TDTx shall make its records available for inspection in accordance with this Section 4.2.2 for a period of [***] following the end of the calendar year to which they pertain. TDTx shall also require any Affiliates to make their records
available for inspection by Licensors, in the same manner as provided in this Section 4.2.2. 
 [***] per calendar year, Licensors may
cause a certified public accountant ‘ selected by Licensors and reasonably acceptable to TDTx to inspect such records during regular business hours; provided, however, Licensors may [***]. In conducting inspections under this
Section 4.2.2, TDTx agrees that Licensors’ accountant may have access to all records which Licensors reasonably believe to be relevant to calculating royalties owed to Licensors under Article 3. TDTx may require the accountant to sign a
customary nondisclosure agreement prior to undertaking any such inspection, and any and all books, records, reports and other documents inspected by such accountant shall be deemed TDTx’s Confidential Information. Licensors may receive a
summary of the accountant’s findings but shall not permit the accountant to disclose such books, records, reports and other documents to Licensors. 

If the inspections show an underpayment of any payment owed to Licensors under Article 3, TDTx shall pay Licensors the unpaid amounts due
hereunder, plus interest as set forth in Section 3.12, within [***] after receiving a written audit report from the accountant. Licensors are responsible for the cost of any inspection, unless the examination shows an underreporting in excess
of [***] for any [***] period, in which case TDTx shall reimburse Licensors for the cost of the inspection within [***] of receipt of an invoice. 

ARTICLE 5 
 JOINT
STEERING COMMITTEE 
 5.1 Formation and Representatives. Promptly after execution of this Agreement, the Parties shall
establish a steering committee (the “Joint Steering Committee” or “JSC”). Each Party shall name a mutually agreed upon equal number of [***] for the Joint Steering Committee, each of whom shall be
[***]. 
 5.2 JSC Chairman. The chairperson of the JSC shall be initially selected by [***] and shall rotate among Lonza and
MEE from meeting to meeting. The role of the chairperson shall be to prepare an agenda for the meetings of the JSC, convene and preside at meetings of the JSC and to ensure the preparation and distribution of minutes, but the chairperson shall
otherwise have no additional powers or rights beyond those held by the other JSC representatives. 
 5.3 Meetings by the JSC.
Until such time when the diligence obligations of TDTx under Article 6 expire, the Joint Steering Committee shall meet [***] during the Term of the Agreement, or as otherwise necessary or mutually agreed by the Parties or as may reasonably be
requested by any Party on an ad hoc basis as necessary. Such meetings may be conducted by videoconference, teleconference or in person, as determined by the Parties. The Joint Steering Committee shall not have the authority to approve any activities
by TDTx or its Affiliates or Sublicensees under this Agreement, but (i) shall have the right to serve as a forum for review and discussion between the Parties with respect to, among other things, (a) review of the sublicensing strategy of
TDTx to ensure consistency with the terms and conditions of this Agreement and share sublicenses granted to Third Parties under the Agreement for commercialization and development efforts, (b) review the progress of the commercialization and
development plans, efforts and objectives of TDTx, including sales, marketing, distribution and support of the Ancestral Technology, (c) review the progress of the sales and marketing of the Ancestral Technology and exchange information related
thereto, (d) review option rights granted to biological targets and transgenes by TDTx, and review the requests of Existing Third Party Licensees/Sublicensees for the naming of Unnamed Option Rights thereunder; and (e) review and discuss
all 3-way external communications by the Parties and press releases and (ii) shall have, solely with respect to the members of the JSC from Lonza and MEE, and solely to the extent that the members from
Lonza and MEE unanimously agree, the right to approve any request for an exception to any sublicense requirements under this Agreement, but excluding right to approve any request to change diligence and payment terms. For clarity, the JSC shall not
have any ability or authority to amend, waive, or modify the terms of this Agreement. 

  
 22. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 6 

OPERATIONS UNDER THE LICENSE 

6.1 Diligence Obligations. 

6.1.1 General Obligations. With respect to only those programs ([***]) of TDTx or its Affiliates that TDTx intends to apply
towards meeting its Minimum Potential Revenue Stream obligations as stated under Section 6.3, and for each program of a Sublicensee, within [***] after the Effective Date, and as updated within [***] after the start of every Calendar Year
thereafter during the Term, TDTx shall provide Licensors with a bona fide written business plan (“General Development Plan”) that describes: 

(a) TDTx’s, its Affiliates and Sublicensees efforts during the prior year for researching, developing and commercializing
Licensed Products in the Field of Use, including (i) information regarding specific Licensed Products in development and their specific applications; (ii) key activities and milestones achieved and status of applications for INDs, CTAs or
equivalents and regulatory approvals; and (iii) [***]; 
 (b) a list of all new sublicense transactions completed and [***]; and

 (c) TDTx’s business [***] goals and objectives for [***]. 

The General Development Plan must contain a sufficient level of detail for Licensors to assess whether TDTx is in compliance with its
obligations under Section 6.1.2 and an outline of TDTx’s, its Affiliates and Sublicensees intended efforts for the subsequent [***] including [***]. TDTx shall also provide Licensors with [***] and annual report to investors which shall
include [***]. 
 6.1.2 Licensed Product Minimum Diligence Obligations. Applicable to TDTx, only for those programs ([***]) of
TDTx or its Affiliates that TDTx intends to apply towards meeting its Minimum Potential Revenue Stream obligations as stated under Section 6.3, and applicable for each program of its Sublicensees, TDTx shall, or shall cause its Affiliates
and/or Sublicensees as applicable to, use Commercially Reasonable Efforts to achieve the following development objectives with respect to each Licensed Product it develops in the Field of Use on its own or with its Affiliates or Sublicensees: 

(a) [***]; 
 (b)
[***]; 
 (c) [***]; 

(d) [***]; and 

(e) [***]. 

  
 23. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 For the avoidance of doubt, TDTx shall not be required to cause its Sublicensees to use
Commercially Reasonable Efforts to achieve the foregoing development objectives to the extent such objectives have already been achieved as of the date the relevant Sublicense was granted. 

6.1.3 Failure to Achieve Development Objectives. With respect to only those programs ([***]) of TDTx or its Affiliates that TDTx
intends to apply towards meeting its Minimum Potential Revenue Stream obligations as stated under Section 6.3, and for each program of a Sublicensee, the following provisions of this Section 6.1.4 shall apply to TDTx (or its Affiliate or
Sublicensee as applicable). 
 In the event that, despite the use of Commercially Reasonable Efforts, TDTx becomes aware that, due to any
relevant scientific, regulatory, safety, development, or commercial circumstances beyond the reasonable control of TDTx or any of its Affiliates or Sublicensees, as applicable, (a) any of the development or regulatory or commercial launch
milestone dates set forth in Section 6.1.2 will not be achieved or (b) any [***] will not be achieved, or (c) it will be unable to [***], then TDTx will notify Licensors in writing via the JSC in advance of such failure to achieve the
expected development or regulatory or commercial launch milestone dates, and the Parties will confer in good faith via the JSC to discuss a revised General Development Plan that is reasonably acceptable to TDTx and Licensors and mitigates or
otherwise takes into account such circumstances to the extent reasonably feasible in view of [***]. For the avoidance of doubt, [***]. Licensors shall notify TDTx via the JSC of any objections to any revised General Development Plan within [***]
after submission by TDTx to the JSC, failing which such General Development Plan shall be deemed approved by Licensors. In the event that Licensors provide TDTx with timely notice via the JSC of its objection to any revised General Development Plan
and, following at least [***] of good faith discussions and efforts to reach agreement on a revised General Development Plan, the Parties cannot agree on a reasonably acceptable revision or other remedy, then Licensors may request that TDTx provide
further evidence of its Commercially Reasonable Efforts to achieve the relevant milestone set forth above. If, and only if, after reviewing such further information requested and provided, Licensors make a determination that TDTx has failed to
demonstrate that it has used Commercially Reasonable Efforts to meet its diligence obligations as stated under this Article 6 for any Licensed Product, Licensors shall notify TDTx of such determination in writing and may treat such failure to meet
its diligence obligations as a material breach of this Agreement. Any such allegation of breach shall be subject to TDTx’s rights under this Agreement to dispute and/or cure it. 

6.2 Minimum Capital Funding. TDTx shall be required to have a Minimum Capital Funding according to the following: 

6.2.1 During the time period from the Effective Date of this Agreement until the [***], TDTx will use Commercially Reasonable Efforts to
raise a total of at least [***] across all fundraising rounds, tranches and sources to fund its operations, including cash for the purchase of capital stock, debt financing, lines of credit, grant funding and other sources of non-dilutive capital such as collaborative R&D funding, and Sublicense Income (net of any Sublicense Income Payment to Licensors) (collectively referred to as “Capital Funding”). 

6.2.2 During the time period from the Effective Date of this Agreement until [***] TDTx will use Commercially Reasonable Efforts to
raise a total of at least [***] in Capital Funding. 
 6.2.3 In the event that TDTx has not actually received funding in the total
amount described above in Section 6.2.1 or Section 6.2.2, despite having used Commercially Reasonable Efforts to secure funding in that amount, but is expected to have received such amount if all amounts that are then committed under
binding definitive agreements or under ongoing bona fide term sheet negotiations with third parties under pending additional tranches of funding that are due and expected within the subsequent [***] period, then TDTx shall not be considered in
breach of the relevant section and the Parties shall discuss and consider in good faith and shall make a reasonable adjustment to the total amounts described above, or an extension to such period as may be reasonable in the circumstances. 

  
 24. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.3 Minimum Potential Revenue Stream Requirements. 

6.3.1 TDTx shall be required to achieve, either by the progression by TDTx or its Affiliate of its own internal programs (such programs
to be based on and defined by the relevant biological target or transgene or Licensed Product) that are not the subject of any Sublicense, or from Sublicenses to the Licensed Products, a minimum Potential Revenue Stream amount for all Licensed
Products in each Contract Year for the [***] according to the following requirements (the “Minimum Potential Revenue Stream”): 

(a) [***]; 
 (b)
[***]; 
 (c) [***]; and 

(d) [***]. 

6.3.2 Potential Revenue Stream Rollover. Notwithstanding the foregoing, if TDTx, in a given Contract Year, achieves a total
Potential Revenue Stream that exceeds the Minimum Potential Revenue Stream requirement for that Contract Year, then TDTx will be permitted to apply the excess Potential Revenue Stream to subsequent Contract Years to reduce the Contract Year Minimum
Potential Revenue Stream requirements in the subsequent Contract Years. For example, if [***]. For clarity, in the event that [***]. 

6.3.3 Penalty For Failure To Meet Minimum Potential Revenue Stream. In the event that TDTx fails to satisfy any such Minimum
Potential Revenue Stream requirement for a relevant Calendar Year, TDTx shall be required to satisfy one of the following three options, such option to be selected at the sole discretion of TDTx. If TDTx chooses [***]: 

(a) Option One: Penalty Payments. Pay the following relevant penalty payments (the “Penalty Payments”):

 (i) [***]. 

(ii) [***]. 

(b) Option Two: Amend Financial Payments to Licensors. The Parties will confer to negotiate in good faith an amendment to the
financial terms in Article 3 of this Agreement, as applicable, that is [***]. If, after negotiating in good faith for a period of [***], the three Parties fail to agree to an amendment to the financial terms Article 3 of the Agreement], then, unless
mutually agreed between all three of the Parties to further extend the negotiations of the amendment, [***]. 
 (c) Option Three:
Obligation to Sublicense Licensed Transgenes. 
 (i) After receiving notice from MEE or Lonza that there is a Third Party
interested in obtaining a license under the Licensed Intellectual Property with respect to a particular biological target or transgene or Licensed Product, for which TDTx has not [***], (such request, a “Third Party License
Request”), within [***] after TDTx’s receipt of any such notice of a Third Party License Request, TDTx shall [***]. Such notice from MEE or Lonza shall be [***]. 

(ii) Negotiation of Sublicense. TDTx shall [***] commence good faith negotiations to enter into a Sublicense with the Third
Party that submitted the Third Party License Request. So long as the relevant Third Party [***], TDTx shall [***]. In no event shall TDTx be required, in connection with the execution of any Sublicense, to [***]. Upon execution and delivery of such
Sublicense, the Sublicense shall [***]. 

  
 25. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (iii) [***]. 

6.4 Regulatory Matters. As between TDTx and Licensors, TDTx shall own and maintain all Regulatory Approvals for the Licensed
Product in its, or its Affiliates or Sublicensees, own name and shall act as the sole point of contact for all communications with Regulatory Authorities in connection with the development, commercialization and manufacturing of the Licensed
Product. Licensors shall provide TDTx with all reasonably requested assistance in connection TDTx’s filings and correspondence with Regulatory Authorities. 

6.5 Other Government Laws. TDTx shall comply with, and ensure that its Affiliates and Sublicensees comply with, all mandatory
and applicable government statutes and regulations that relate to Licensed Products. These include but are not limited to FDA statutes and regulations, the Export Administration Act of 1979, as amended, codified in 50 App. U.S.C. 2041 et seq. and
the regulations promulgated thereunder or other applicable export statutes or regulations. 
 6.6 Patent Marking. To the
extent commercially feasible and consistent with prevailing business practices and applicable law, TDTx shall mark, and shall require its Affiliates and Sublicensees to mark, all Licensed Products sold in the United States with the word
“Patent” and the number or numbers of the Patent Rights applicable to the Licensed Product. 
 6.7 Ongoing
Communication. Subject to any obligations of confidentiality to which each respective Party may be subject, each Party shall make appropriate personnel available from time to time at the other Party’s reasonable request to answer questions
from the other Party concerning the status of the development of the Ancestral Technology and to discuss and attempt to resolve any issues or concerns a Party may have. 

ARTICLE 7 
 TDTX-LONZA STRATEGIC MANUFACTURING RELATIONSHIP 
 7.1 Manufacturing Agreements. TDTx
and Lonza will enter into good faith negotiations for a definitive manufacturing services agreement wherein TDTx and its Affiliates and Sublicensees will obtain the right to earn and obtain preferential rights to manufacturing services from Lonza in
return for TDTx voluntarily fulfilling certain “frequent flyer” criteria related to the manufacture of Licensed Products with Lonza, as further outlined in Schedule H. 

ARTICLE 8 

CONFIDENTIALITY 

8.1 Non-Disclosure Obligation. Each Party agrees, during the term of this Agreement, and
for [***] thereafter, to employ all reasonable efforts to maintain the other Party’s Confidential Information secret and confidential, such efforts to be no less than the degree of care employed by such Party to preserve and safeguard its own
confidential information. The Receiving Party shall not use the Disclosing Party’s Confidential Information for any purpose other than as expressly permitted under this Agreement and shall not disclose or reveal the Disclosing Party’s
Confidential Information to anyone except employees or agents of or consultants or advisors to the Receiving Party or its Affiliates (and in the case of TDTx as the Receiving Party, its actual or bona fide potential Sublicensees, licensees,
subcontractors, collaborators, investors, lenders and/or acquirers) (collectively, “Representatives”) who have a need to know the information and who are subject to written obligations of confidentiality under which they are
required to abide by the obligations of confidentiality and restrictions on use set forth in Section 8 and are advised by the Receiving Party of the confidential nature of the Confidential Information. The Receiving Party shall be responsible
for any breach of this Article 8 by its Representatives. The Receiving Party’s obligations under this Section 8.1 shall not extend to any information that: 

8.1.1 at the time of disclosure is in the public domain; 

  
 26.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 8.1.2 becomes part of the public domain, by publication or otherwise, through no
breach of this Agreement by the Receiving Party; 
 8.1.3 at the time of disclosure is already in possession of the Receiving Party,
as established by contemporaneous written records; 
 8.1.4 is lawfully provided to the Receiving Party, without restriction as to
confidentiality or use, by a Third Party not known by the Receiving Party to be subject to any obligation of confidentiality with respect to such information; or 

8.1.5 is or was independently developed by a Party without use of or reference to the other Party’s Confidential Information, as
established by contemporaneous written records. 
 8.2 Government-Required Disclosure. If a duly constituted government
authority, court or regulatory agency orders that a Party hereto disclose information subject to an obligation of confidentiality under this Agreement, such Party shall comply with the order, but shall notify the other Party as soon as possible, so
as to provide the said Party an opportunity to apply to a court of record for relief from the order or to limit the scope of the order. In addition, nothing in this Agreement shall prohibit the Receiving Party from disclosing Confidential
Information to the extent such disclosure is necessary to comply with the rules of any stock exchange, so long as the Receiving Party uses reasonable efforts to seek confidential treatment therefor. 

ARTICLE 9 
 INTELLECTUAL
PROPERTY 
 9.1 Ancestral Technology Patent Preparation, Filing, Prosecution and Maintenance. 

9.1.1 Responsibility. MEE shall be responsible for prosecuting and maintaining all patents and patent applications within the
Ancestral Technology Patent Rights. Title to all such patents and patent applications shall reside in MEE. MEE shall have full and complete control over all patent matters in connection therewith under the Ancestral Technology Patent Rights. For
purposes of this Agreement, patent prosecution includes [***]. MEE shall provide, or cause its agent to provide, copies of all proposed patent application filings and all office actions and other material correspondence with the United States Patent
Office or the various foreign patent offices to TDTx and shall provide to TDTx a timely opportunity to review, comment and provide input on all such proposed patent application filings and on all decisions on where to file patent applications and on
all office action responses and material correspondence with patent offices, and all of TDTx’s comments and input shall be taken into account with good faith consideration by MEE. TDTx designates the following individual or department for
receiving the patent-related correspondence: 
 Chief Legal Officer 

TDTx, Inc. 
 One Broadway, 14th
Floor, Kendall Square 
 Cambridge, MA 02142 

MEE shall make itself available to consult with TDTx on matters relating to preparing, filing, prosecuting or maintaining any of the applications or patents
within the Ancestral Technology Patent Rights, solely with respect to matters which are reasonably likely to pertain to the practice of the Ancestral Technology Patent Rights in the Field of Use, which matters may be of particular interest to TDTx,
and MEE shall consider any comments received from TDTx with respect thereto in good faith. 

  
 27. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 9.2 Election Not to File and Prosecute Patent Rights. If MEE elects not to
file or to continue to prosecute or maintain any Ancestral Technology Patent Rights directly related to the Field of Use in any particular country or territory, then it shall notify TDTx in writing at least [***] before any deadline applicable to
the filing, prosecution or maintenance of such Ancestral Technology Patent Rights in the relevant country or territory, as the case may be, or any other date by which an action must be taken to establish or preserve such Ancestral Technology Patent
Rights in such country or territory. In such case, and subject to the rights of Existing Third Party Licensees/Sublicensees as of the Effective Date to file, prosecute or maintain such Patent Rights in such country or territory, TDTx shall have the
right, but not the obligation, with respect to the Ancestral Technology Patent Rights directly related to the Field of Use, to pursue the filing or support the continued prosecution or maintenance of such Ancestral Technology Patent Rights in such
country or territory using patent counsel that is reasonably acceptable to MEE, and, subject to the rights of Existing Third Party Licensees/Sublicensees as of the Effective Date to file, prosecute or maintain such Patent Rights in such country or
territory, and may delegate any such right to any of its Affiliates, or Sublicensees. 
 9.2.1 If TDTx or any of its Affiliates, or
Sublicensees assumes responsibility as permitted under Section 9.2 for the prosecution and maintenance of any Ancestral Technology Patent Rights in the Field of Use in any country or territory, and at any time thereafter elects not to continue
prosecution or maintenance of any such Ancestral Technology Patent Rights in such country or territory, then TDTx shall notify MEE in writing at least [***] before any deadline applicable to the filing, prosecution or maintenance of such Ancestral
Technology Patent Rights in such country or territory, as the case may be, or any other date by which an action must be taken to establish or preserve such Ancestral Technology Patent Rights in such country. If TDTx elects not to assume
responsibility for the prosecution and maintenance of any Ancestral Technology Patent Rights in such country or territory, then it will notify MEE within [***] after TDTx’s receipt of the notice from MEE referred to in Section 8.2.1. 

9.2.2 If TDTx (or any of its Sublicensees) does not continue prosecution or maintenance of any abandoned Ancestral Technology Patent
Rights, then such Ancestral Technology Patent Rights shall not extend the Royalty Term ([***]). 
 9.3 Notice. TDTx shall
provide prompt notice to MEE of any information that comes to its attention that TDTx reasonably believes is likely to materially affect the patentability, validity or enforceability of any patent application or patent within the Ancestral
Technology Patent Rights. 
 9.4 Relinquishing Rights. TDTx may surrender its licenses under any of the patents or patent
applications within the Ancestral Technology Patent Rights in any country or territory of the Territory by giving [***] advance written notice to MEE. However, if TDTx is surrendering any patent or application within the Ancestral Technology Patent
Rights on which an interference proceeding or opposition has been declared or filed, the notice period is [***]. If TDTx so surrenders its rights, it will remain responsible for its portion of the patent-related expenses incurred by MEE during the
applicable notice period. Thereafter, TDTx will have no further obligation to pay any patent expenses for the patents or patent applications that it surrendered. Notwithstanding the foregoing, if such surrender is with respect to all Ancestral
Technology Patent Rights in all countries licensed to TDTx under this Agreement, and thus results in termination of all of TDTx’s other rights under this Agreement, then the termination notice provision in Section 11.3 below shall apply.

 9.5 Intellectual Property Rights. 

9.5.1 Licensed Intellectual Property Rights. Except as expressly stated in this Agreement, TDTx will not, under this Agreement,
acquire any right, title, license or other interest in any Licensed Intellectual Property. 
 9.5.2 Lonza Intellectual Property
Rights. Except as expressly stated in this Agreement, neither TDTx nor MEE will, under this Agreement, acquire any right, title, license or other interest in any Lonza Intellectual Property. 

  
 28. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 9.5.3 MEE Intellectual Property Rights. Except as expressly stated in this
Agreement, neither TDTx nor Lonza will, under this Agreement, acquire any right, title, license or other interest in any MEE Intellectual Property. 

9.5.4 TDTx Intellectual Property Rights. Neither MEE nor Lonza will, under this Agreement, acquire any right, title, license or
other interest in any TDTx Intellectual Property. 
 9.5.5 Inventorship and Ownership of Inventions. Except as otherwise
expressly stated to the contrary herein, the ownership of all Intellectual Property made, conceived, reduced to practice or otherwise arising under or in connection with this Agreement will be determined in accordance with inventorship. Inventorship
of all Intellectual Property will be determined in accordance with the applicable patent laws of the United States. 
 9.5.6 TDTx
Owns. TDTx shall own all right, title and interest in all TDTx Intellectual Property conceived by employees, contractors or other individuals working for the benefit of TDTx and/or its Affiliates, either solely or jointly, during and in the
course of the Agreement, including any intellectual property that is an improvement of, modification of, or derivative of, any TDTx Intellectual Property; provided, however, that the provisions of Section 18.1 on MEE Policy
requirements shall apply with respect to any intellectual property generated by any consultant engaged by TDTx under a consulting agreement if such consultant is an employee or faculty member of MEE. 

ARTICLE 10 
 PATENT
INFRINGEMENT AND ENFORCEMENT 
 10.1 Notice. If any Party learns of an infringement, unauthorized use, misappropriation or
ownership claim or threatened infringement or other such claim in the Field of Use by a Third Party with respect to any Licensed Intellectual Property, such Party shall promptly notify the other Parties and shall provide available evidence of such
infringement. Any such infringement, unauthorized use, misappropriation or ownership claim or threatened infringement or other such claim is referred to herein as “Infringement”. 

10.2 Enforcement. 

10.2.1 Procedure. MEE shall have the first right, but not the duty, to institute Infringement actions against Third Parties. If
MEE does not initiate efforts to cease such Infringement or institute an Infringement proceeding against an offending Third Party within [***] after being notified or otherwise learning of such Infringement, TDTx shall have the right, but not the
duty, solely within the Field of Use, to initiate efforts to cease such Infringement or institute an Infringement proceeding against an offending Third Party with respect to any Infringement by such Third Party. If, within [***] from which it has a
right to initiate efforts to cease such Infringement or institute an. Infringement proceeding against an offending Third Party, TDTx does not initiate efforts to cease such Infringement or institute an Infringement proceeding, then Lonza shall have
the right, but not the duty, to initiate efforts to cease such Infringement or institute an Infringement proceeding against the offending Third Party. Before TDTx commences any legal proceeding with respect to the Infringement, TDTx shall consider
in good faith the views of MEE, [***]. If requested by TDTx, Lonza and/or MEE will join, such proceeding as a party-plaintiff if such joinder is required by law (as reasonably determined by TDTx) to maintain standing, at TDTx’s expense. 

10.2.2 TDTx’s Right to Join. TDTx shall have the right to join any legal proceeding brought by MEE and/or Lonza under this
Section 10.2 solely with respect to Infringements in the Field of Use and to fund a pro-rata share of the out-of-pocket
costs and expenses associated with the legal proceeding incurred by the party leading the case (i.e., MEE and or Lonza, as the case may be), from the date of joining based on allocating an equal portion of such expenses to all parties (including any
Third Parties) joining in such proceeding. If TDTx elects to join as a party plaintiff pursuant to this Section 10.2.2, TDTx may jointly participate in the action with MEE and/or Lonza, as applicable, but where MEE is a party its counsel will
be lead counsel and where MEE is not a party but Lonza is a party, TDTx’s counsel will be lead counsel. 

  
 29. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.2.3 Lonza and MEE’s Right to Join. Lonza and MEE independently have
the right to join any Infringement proceeding that is brought by TDTx for the Field of Use as permitted under this Section 10.2 and shall be responsible for funding its pro rata portion of the out-of-pocket costs and expenses associated with the legal proceedings incurred by TDTx from the date of joining based on allocating an equal portion of such costs and expenses to TDTx, MEE, Lonza and any
Third Party joining in such proceeding, as applicable. If MEE and/or Lonza elect to join as a party plaintiff pursuant to this Section 10.2.3, MEE and/or Lonza may jointly participate in the action with TDTx, but TDTx’s counsel will be
lead counsel. 
 10.2.4 Cooperation. Each Party shall execute all necessary and proper documents, take such actions as shall
be appropriate to allow the other Party to institute and prosecute such Infringement actions and shall otherwise cooperate in the institution and prosecution of such actions (including, without limitation, consenting to being named as a nominal
party thereto) at the initiating Party’s request and expense. 
 10.2.5 Costs and Expenses. The costs and expenses of any
Infringement action (including fees of attorneys and other professionals) shall be borne by the Party instituting the action, or, if the Parties elect to cooperate in instituting and maintaining such action, such costs and expenses shall be borne by
the Parties in such proportions as set forth in Sections 10.2.2 and 10.2.3, as applicable. 
 10.2.6 Settlement. Regardless of
whether MEE and/or Lonza is joined or joins any Infringement proceeding initiated by TDTx pursuant to this Article 10, no settlement, consent judgment or other voluntary final disposition of the Infringement proceeding may be entered into without
the consent of MEE and Lonza unless such voluntary disposition (a) includes a full release of MEE’s and Lonza’s liability and no admission of guilt or other wrongdoing on the part of MEE or Lonza with respect to the claim(s) giving
rise to the legal proceeding, (b) provides for no obligations or liability on the part of MEE and Lonza and (c) does not adversely affect the validity or enforceability of the Ancestral Technology Patent Rights. For the avoidance of doubt,
for as long as it remains the exclusive licensee of the Licensed Intellectual Property, TDTx shall have the right, without MEE’s or Lonza’s consent, to grant Sublicenses, that meet the obligations of this Agreement, to Third Parties for
the purpose of settling litigation. 
 10.3 Distribution of Amounts Paid by Third Parties. Any award paid by Third Parties as
a result of such an Infringement action (whether by way of settlement or otherwise) solely with respect to the Field of Use shall be applied first to [***]. Any such amounts awarded [***]. 

10.4 Declaratory Judgment or Infringement Actions. In the event that any Third Party initiates an Infringement action in the
form of a declaratory judgment action or similar action alleging the invalidity or unenforceability of the Ancestral Technology Patent Rights, or if any Third Party brings an Infringement action against TDTx or its Affiliates, or Sublicensees
because of the exercise of the licenses granted under this Agreement (any of the foregoing actions, “Third Party Infringement Actions”), then TDTx shall have the right to defend such Third Party Infringement Action under its
own control and at its own expense; provided, however, that MEE and/or Lonza shall have the right to intervene and assume sole control of such defense, at its own expense. The Party in control of the defense of any Third Party
Infringement Action shall not enter into any settlement, consent judgment or other voluntary final disposition of any action under this Section 10.4 without the consent of MEE and the non-controlling
Party, unless such voluntary disposition (a) includes a full release of the MEE’s and the non-controlling Party’s liability and no admission of guilt or other wrongdoing on the part of MEE and
the non-controlling Party with respect to the claim(s) giving rise to the legal proceeding, (b) provides for no obligations or liability on the part of MEE and the
non-controlling Party, and (c) does not adversely affect the validity or enforceability of the Ancestral Technology Patent Rights. 

  
 30. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 10.5 Delegation. TDTx shall have the right to delegate any of its rights and
obligations under this Article 10 to any of its Sublicensees upon written notice to Licensors, in which case all references to TDTx, as they relate to such delegated rights and obligations, shall refer to the relevant Sublicensee. 

ARTICLE 11 
 TERM AND
TERMINATION 
 11.1 Term. Unless terminated earlier under the provisions of this Agreement, the term of this Agreement
(the “Term”) shall commence on the Effective Date and shall expire on the expiration date of the last to expire Royalty Term. 

11.2 Termination by Licensors. Licensors shall have the right to terminate this Agreement: 

11.2.1 if TDTx materially breaches any of its diligence obligations under Article 6 and TDTx has not cured such breach within [***]
after receiving written notice from Licensors; 
 11.2.2 In its entirety if TDTx fails to pay on schedule any milestone or royalty or
other payment not subject to a good faith dispute, which is payable with respect to a particular Licensed Product under Article 3 of this Agreement, and TDTx has not cured the default by making the required payment, together with interest due,
within [***] of receiving a written notice of default from Licensors requesting such payment, unless such failure is due to the failure of a Sublicensee to pay corresponding amounts due to TDTx under the relevant Sublicense Agreement, in which case
termination by Licensors shall only be effective if TDTx fails to cure such breach within [***] after receipt of such corresponding amounts from the relevant Sublicensee; 

11.2.3 (1) in its entirety, if TDTx or any of its Affiliates, or (ii) in part on a Licensed Product-by-Licensed Product basis, if a Sublicensee under the Ancestral Technology Patent Rights, in either case, (clauses (i) or (ii)) initiates or participates as a plaintiff in any legal,
administrative or declaratory action or proceeding in any jurisdiction that seeks to challenge the validity or enforceability of any of the Ancestral Technology Patent Rights (a “Patent Challenge”) and such Patent Challenge
is not required under a court order or subpoena and is not a defense against a claim, action or proceeding asserted by Lonza, MEE or their Affiliates or licensees against TDTx, its Affiliates, or its Sublicensees; provided, however,
Licensors may not terminate this Agreement if (a) such Patent Challenge is brought by a Sublicensee and (b) TDTx or any its Affiliates terminates such Sublicensee’s sublicense to the applicable Ancestral Technology Patent Right(s)
within [***] of Licensors providing notice to TDTx of such Patent Challenge; 
 11.2.4 In its entirety, if TDTx materially breaches
any of its obligations to procure and maintain insurance under Section 12.2, unless TDTx has cured the breach within [***] of receiving written notice from Licensors specifying the nature of the breach; 

11.2.5 In its entirety, if TDTx materially breaches any provision of this Agreement other than for the circumstances described as set
forth in Sections 11.2.1-11.2.4, if Licensors provide written notice to TDTx specifying the nature of the material breach, unless TDTx has cured the breach within [***] of receiving such written notice from
Licensors; or 
 11.2.6 In its entirety if TDTx becomes judicially declared insolvent or has a petition in bankruptcy filed for or
against it, unless (a) TDTx provides reasonable evidence to Licensors showing that it is no longer insolvent within [***] of receiving such termination notice from Licensors or (b) such bankruptcy petition is dismissed or resolved within
[***] of being filed. 
 Notwithstanding anything to the contrary, termination by Licensors pursuant to this Section 11.2 due to acts
or omissions of one or more Sublicensees shall be solely with respect to the Licensed Product(s) or the program relating to potential Licensed Products directed to the relevant biological target or transgene to which such Sublicensee(s) have rights
under the relevant Sublicense(s). 

  
 31. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.3 Termination by TDTx. TDTx shall have the right to terminate this
Agreement in its entirety, for any reason with or without cause, by giving Licensors [***] prior written notice. In the event that this Agreement is terminated by TDTx pursuant to this Section 11.3 due to a material breach of this Agreement by
Licensors, which breach remains uncured as of the effective date of termination, and without limiting TDTx’s rights under Section 3.14, TDTx shall also be entitled to set-off against any monies
payable to Licensors hereunder all amounts TDTx reasonably believes constitute its direct damages incurred by such breach, subject to final resolution or settlement in accordance with Sections 16.1 and/or 16.2, without prejudice to any and all of
TDTx’s rights to bring an action against Licensors for damages and any other available remedies in law or equity. In the event TDTx sets off amounts it reasonably believes constitute its direct damages incurred by such breach and, after a final
resolution or settlement of any dispute arising from such breach in accordance with Sections 16.1 and/or 16.2, the actual damages determined by the Parties or by the arbitrator, as the case may be, to have been incurred by TDTx are less than the
amounts so offset, TDTx shall promptly (and in any case within [***] of such final resolution) pay the difference to Licensors, plus interest at the rate of [***], calculated from and after the date TDTx exercised its right to set-off such amount. 
 11.4 Material Breach Dispute. Any dispute regarding an alleged
material breach of this Agreement shall be resolved in accordance with Article 16 hereof. Notwithstanding anything to the contrary contained in Section 11.2 or elsewhere in the Agreement, the applicable cure period for any alleged breach that
is in dispute shall be tolled pending the resolution of such dispute pursuant to Article 16, and it is understood and acknowledged that, during the pendency of a dispute pursuant to Article 16, all of the terms and conditions of this Agreement shall
remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement. 
 11.5
Effect of Termination. 
 11.5.1 Expiration of Royalty Term. Upon expiration of the Royalty Term in a particular
country for any Licensed Product ([***]), the license granted to TDTx under this Agreement with respect to such Licensed Product and only for such Licensed Product will become irrevocable, perpetual, and fully-paid in that country and shall remain
exclusive in that country. TDTx shall have no further obligations under Article 6 with respect to such Licensed Product in that country. 

11.5.2 Termination of License Rights. Upon termination of this Agreement for any reason with respect to all Licensed Products,
the Agreement shall be terminated in its entirety and all license rights granted under Section 2.1 shall terminate immediately and automatically upon the effective date of such termination. 

11.5.3 No release. Upon termination of this Agreement for any reason, nothing in this Agreement may be construed to release any
Party from any obligation that accrued prior to the effective date of the termination. 
 11.5.4 Survival. The following
provisions shall survive any expiration or termination of this Agreement for any reason: [***]. 
 11.5.5 Inventory. TDTx and
any Affiliate(s) may, after the effective date of termination for any or all Licensed Transgenes, sell all Licensed Products for such Licensed Transgenes that are in inventory as of the date of written notice of termination, and complete and sell
Licensed Products for such Licensed Transgenes which TDTx can clearly demonstrate were in the process of manufacture as of the date of written notice of termination, provided that TDTx shall pay to Licensors the royalties thereon as required
by Article 3 and shall submit the reports required by Article 4 on the sales of Licensed Products. 
 11.5.6 License Survival.
In the event of any termination of the Amended and Restated Lonza-MEE Agreement, where such termination has not been caused by any action or inaction on the part of TDTx, or any of its Affiliates or
Sublicensees in connection with their sublicensing the Licensed Intellectual Property, such termination of the Amended and Restated Lonza-MEE Agreement resulting in the termination of this Agreement shall be
without prejudice to the rights of TDTx, and MEE shall, if requested by TDTx, enter into a license agreement directly with TDTx (the “Replacement License Agreement”) on substantially the same terms and conditions as those set
forth in this Agreement; provided, however, that [***]. TDTx is named as a Third Party beneficiary of Section 8.8 of the Amended and Restated Lonza-MEE Agreement with the right to enforce it
directly against MEE. 
  

  
 32. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.5.7 Sublicense Survival. In the event of any termination of this Agreement
where such termination affects any Sublicense involving any Licensed Products, and such termination has not been caused by any action or inaction on the part of any Sublicensee of such Licensed Products and such Sublicensee is, as of the effective
date of such termination, current and fully compliant with all of its material obligations and with all of the terms and conditions of such Sublicense and is not otherwise in any uncured material breach of its obligations under its Sublicense from
TDTx (such Sublicensee, a “Compliant Sublicensee”), such termination of this Agreement shall be without prejudice to the rights of such Compliant Sublicensee of such Licensed Products of TDTx, and Licensors shall, if
requested in writing by the Compliant Sublicensee, within a period not to exceed [***] from the date of such written request, enter into good faith negotiations for a definitive license agreement directly with the Compliant Sublicensee (the
“Replacement Sublicense Agreement”) on substantially the same terms and conditions as those set forth in this Agreement; provided, however, that [***]. In the event that any such Replacement Sublicense involves
only a pass-through Sublicense of the same or substantially the same scope of sublicensed intellectual property and for the same or substantially the same licensed field of use for the sublicensed intellectual property rights to be granted to such
Compliant Sublicensee relative to the original Sublicense, and does not involve any additional material performance obligations or any other material obligations such as indemnification obligations or other obligations, liabilities, covenants, or
responsibilities for either MEE or Lonza other than the grant of the continued Sublicense rights under the same or substantially the same scope of licensed intellectual property comparable in scope and field to those rights that existed under the
Sublicense that was in place directly with TDTx, Licensors will enter into such Replacement Sublicense with such Compliant Sublicensee during such [***] negotiation period and will not have the right in such case to deny the grant of any such
Replacement Sublicense to any Compliant Sublicensee. 
 11.5.8 No Liability for Termination. Any termination pursuant to this
Article 11 shall be without any additional liability or obligation of the terminating party, other than with respect to any liability due to an uncured breach of this Agreement prior to termination. 

ARTICLE 12 

INDEMNIFICATION AND INSURANCE 

12.1 Indemnification. 

12.1.1 By TDTx 

(a) At TDTx’s sole expense, TDTx shall indemnify, defend and hold harmless (collectively, “indemnify” or
“indemnification”) each of MEE and Lonza, and each of their respective owners, members and Affiliates and their respective trustees, directors, officers, medical and professional staff, employees, students, volunteers, and agents and their
respective successors, heirs and assigns (the “Indemnitees”), against any and all liability, damage (including direct, indirect, consequential and special damages), loss or expense (including reasonable attorney’s fees
and expenses of litigation) (a “Loss”), incurred by or imposed upon the Indemnitees or any one of them in connection with any Third Party claims, suits, actions, investigations, demands or judgments relating to or arising
from, in whole or part: (i) any theory of product liability (including, but not limited to, actions in the form of contract, tort, warranty, or strict liability) concerning any Licensed Product, process or service made, used, sold or performed
pursuant to any right or license granted under this Agreement, or (ii) any claim by a Third Party that the use by TDTx or by any of its Affiliates or Sublicensees of any Licensed Product, process or service made, used or sold or performed
pursuant to any right or license granted under this Agreement infringes any patent, copyright or trade secret, or (iii) TDTx’s breach of its obligations under this Agreement; except to the extent that TDTx can demonstrate [***] that a Loss
as described in clause (i), (ii) or (iii) hereof directly results from the gross negligence or intentional misconduct of MEE or Lonza and/or the Indemnitees. 

  
 33. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) TDTx agrees, at its own expense, to provide attorneys reasonably acceptable to
Licensors on behalf of the Indemnitees to defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought;
provided, however, that any of the Indemnitees shall have the right to retain its own counsel, at the expense of TDTx, if representation of such Indemnitee by counsel retained by TDTx would be inappropriate because of conflict of
interests of any such Indemnitees and any other party represented by such counsel. TDTx agrees to keep Licensors informed of the progress in the defense and disposition of such claim and to consult with Licensors prior to any proposed settlement.

 (c) This Section shall survive expiration or termination of this Agreement. 

(d) Any limitation of liability within this Agreement shall not limit the extent of TDTx’s and its assigns’ and
successor’s indemnification obligations indicated within this Section. 
 (e) TDTx shall contractually obligate its
Sublicensees to the same or substantially the same indemnification obligations as set forth for TDTx in this Section. 
 12.1.2 By
Lonza. 
 (a) Lonza shall defend TDTx and its Affiliates and each of their respective employees, officers, directors and agents,
and their successors and assigns (“TDTx Indemnitees”) against any and all Claims to the extent [***] attributable to any breach by Lonza of its representations or warranties set forth in Section 14.2 or to the extent
[***] attributable to any uncured material breach by Lonza of this Agreement. Lonza shall indemnify (i.e., pay) any and all Losses finally awarded to such Third Party by a court of competent jurisdiction, or agreed to in monetary settlement, with
respect to any such Claims. Lonza’s obligations pursuant to this Section 12.1.2 shall not apply (i) to the extent that such Claims are subject to the indemnification obligations of TDTx under Section 12.1.1 or attributable to the
gross negligence or willful misconduct of any of the TDTx Indemnitees or MEE Indemnitees, (ii) to the extent that such Claim is attributable to the allegedly infringing use of any TDTx Intellectual Property, (iii) with respect to Claims
arising out of a breach by TDTx of its representations or warranties set forth in Section 13.1 or out of a breach by MEE of its representations set forth in Section 13.3 or (iv) the breach by TDTx or MEE of any of the other provisions
of this Agreement. For clarity, under no condition shall Lonza be responsible for indemnifying, defending or holding harmless MEE Indemnitees for any Claims arising under this Agreement or for indemnifying, defending or holding harmless TDTx for any
Claims arising under this Agreement, to the extent that any such Claim is attributable to the gross negligence or willful misconduct of any MEE Indemnitee or the breach by any MEE Indemnitee of any provision of this Agreement. 

12.1.3 Each indemnifying Party agrees, at its own expense, to provide attorneys reasonably acceptable to the applicable indemnified
Party to defend against any actions brought or filed against the Licensors Indemnitees or TDTx Indemnitees, as the case may be, with respect to the subject of indemnity contained herein. The assumption of control of the defense of a Claim by a Party
pursuant to Section 11.1 or 11.2, as applicable, shall not be construed as an acknowledgement that such Party is liable to indemnify the Licensors Indemnitees or TDTx Indemnitees (as the case may be) in respect of the Claim, nor shall it
constitute a waiver by such Party of any defenses it may assert against any claim for indemnification. In the event that it is ultimately determined that a Party that has undertaken to indemnify the Licensors Indemnitees or TDTx Indemnitees, as the
case may be, is not obligated to indemnify, defend or hold harmless such Licensors Indemnitees or TDTx Indemnitees, the other Party shall reimburse such Party for any and all costs and expenses (including reasonable lawyers’ fees and costs of
suit) and any Losses incurred by such Party in its defense of the Claim with respect to such the applicable indemnitee(s). 
 12.1.4
Each Party’s obligations under Section 11.1.1 or 11.1.2, as applicable, are contingent on the Licensors Indemnitee(s) or TDTx Indemnitee(s), as applicable, giving the indemnifying Party prompt, written notice of the Claim for which
indemnification is sought, primary control over the defense and/or settlement of the Claim, and all reasonably requested information and assistance in connection therewith. The Licensors Indemnitee(s) or TDTx Indemnitee(s), as applicable, shall be
entitled to participate in (but not control) such defense and/or settlement proceedings at their own cost and expense using counsel of their choosing. 

  
 34. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 12.2 Insurance. (a) Beginning at such time as any Licensed Product is
[***], by TDTx, an Affiliate or Sublicensee, TDTx shall, at its sole cost and expense, procure and maintain commercial general liability (herein, “CGL”) insurance [***]. Such limits of insurance may be achieved by primary
insurance policies alone or in combination with excess-liability and/or umbrella-liability insurance policies. [***] for TDTx’s indemnification under this Section. If TDTx’s CGL insurance does not include [***], TDTx shall, at its sole
cost and expense, procure and maintain [***]. Such limits of insurance may be achieved by [***]. Such insurance within this Section shall be primary, at MEE’s discretion, to any insurance maintained by MEE. If TDTx elects to [***]. The minimum
amounts of insurance coverage required under this Section shall not be construed to create a limit of TDTx’s liability with respect to its indemnification under this Section. 

(b) TDTx shall provide MEE, at its request, with written evidence of such insurance and the additional-insured status of the
Indemnitees. TDTx shall provide MEE with written notice at least [***] prior to the cancellation, non-renewal or material change in such insurance; if TDTx does not obtain replacement insurance providing
comparable coverage prior to the expiration of such [***] period, MEE shall have the right to terminate this Agreement effective at the end of such [***] period without notice or any additional waiting periods. 

(c) TDTx shall maintain such insurance, beyond the expiration or termination of this Agreement during (i) the period that any
such product, process, or service is [***]), by TDTx or by a licensee, affiliate or agent of TDTx and (ii) a reasonable period after the period referred to in (c) (i) above which in no event shall be less than [***]. 

(d) Insurance within this Section must be provided by commercial insurance companies with a [***]. 

(e) This Section shall survive expiration or termination of this Agreement. 

(f) Any limitation of liability within this Agreement shall not limit the extent of TDTx’s and its assigns’ and
successors’ insurance obligations indicated within this Section. 
 (g) TDTx shall contractually obligate any Sublicensees and
Distributors to the same insurance obligations as set forth for TDTx in this Section. 
 12.3 Disclaimer of Warranties; Limitation of
Liability 
 12.3.1 NEITHER LONZA NOR MEE MAKES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTIES OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, NON-PUBLIC OR OTHER INFORMATION, OR TANGIBLE RESEARCH PROPERTY, LICENSED OR OTHERWISE
PROVIDED TO TDTx HEREUNDER AND HEREBY DISCLAIMS THE SAME. 
 12.3.2 NEITHER LONZA NOR MEE WARRANTS THE VALIDITY OF THE ANCESTRAL
TECHNOLOGY PATENT RIGHTS LICENSED HEREUNDER NOR MAKES ANY REPRESENTATION WHATSOEVER WITH REGARD TO THE SCOPE OF THE ANCESTRAL TECHNOLOGY PATENT RIGHTS OR THAT SUCH ANCESTRAL TECHNOLOGY PATENT RIGHTS MAY BE EXPLOITED BY TDTx OR ITS AFFILIATE OR
SUBLICENSEE WITHOUT INFRINGING OTHER PATENTS. 

  
 35. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 12.3.3 EXCEPT WITH RESPECT TO ANY BREACH OF ARTICLE 8, NO PARTY, NOR THEIR DIRECTORS,
OFFICERS, EMPLOYEES, OR AGENTS, SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, INCLUDING INCIDENTAL, ECONOMIC DAMAGES OR LOST PROFITS, EVEN IF SUCH
PARTY HAS BEEN INFORMED, SHOULD HAVE KNOWN OR IN FACT KNEW OF THE POSSIBILITY OF SUCH DAMAGES. 
 12.4 Acknowledgement. The
Parties acknowledge and agree that they are entering into this Agreement in reliance upon the exclusions and limitations set forth in this Article 12, and that the same reflect an allocation of risk ([***]) and that the same form an essential basis
of the bargain between the Parties. 
 12.5 Article Survival. This Article shall survive expiration or termination of this
Agreement. 
 ARTICLE 13 

REPRESENTATIONS AND WARRANTIES 

13.1 TDTx’s Representations and Warranties. TDTx represents and warrants to Licensors that: (a) it is
and shall be at all times during the Term a valid legal entity existing under the law of its state with the power to carry on its business as it is currently being conducted; (b) the execution and delivery of this Agreement has been duly
authorized and no further approval, corporate or otherwise, is required in order to execute this valid, binding and enforceable Agreement; and (c) its execution, delivery, and performance of this Agreement shall not conflict in any material
fashion with the terms of any other agreement or instrument to which it is or becomes a party or by which it is or becomes bound. 

13.2 Lonza’s Representations and Warranties and Covenants. Lonza represents and warrants to TDTx that, to the
best of the knowledge of the responsible individuals at Lonza, without having conducted any special inquiry or additional review: (a) it is and shall be at all times during the Term a valid legal entity existing under the law of its state with
the power to carry on its business as it is currently being conducted; (b) the execution and delivery of this Agreement has been duly authorized and no further approval, corporate or otherwise, is required in order to execute this valid,
binding and enforceable Agreement; (c) it is not a party to any agreement that is inconsistent or in conflict with the rights and licenses granted to TDTx hereunder; (d) its execution, delivery and performance of this Agreement shall not
conflict with the terms of any other agreement to which it is a party or by which it is bound; (e) as of the Effective Date, that there are no patents or patent applications, other than the Ancestral Technology Patent Rights, owned or otherwise
Controlled by Lonza the claims of which read on any claims in the Licensed Intellectual Property; (f) as of the Effective Date, no claims have been asserted or threatened against Lonza, nor are there any valid grounds for any claim of any such
kind (1) challenging the validity, effectiveness, or ownership of the Licensed Intellectual Property, and/or (2) to the effect that the use, development or commercialization of Licensed Products using the Licensed Intellectual Property as
contemplated for TDTx under this Agreement infringes or will infringe or misappropriate any intellectual property right of any Third Party; and (g) as of the Effective Date, the Ancestral Technology Patent Rights are not the subject of any
litigation procedure, interference, reissue, reexamination, opposition, appeal proceedings or any other formal legal proceeding. Lonza shall not exercise any right it may have to terminate the Amended and Restated
Lonza-MEE Agreement or otherwise materially amend or modify the Amended and Restated Lonza-MEE Agreement in a way that materially adversely affects TDTx’s rights
hereunder with respect to the Licensed Intellectual Property without the prior written consent of TDTx. 

  
 36. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 13.3 MEE’s Representations. MEE agrees that, to the best of
the knowledge of the responsible individuals at MEE’s Office of Innovation as of the Effective Date, without having conducted any special inquiry or additional review: (a) it is and shall be at all times during the Term a valid legal
entity existing under the law of its state with the power to carry on its business as it is currently being conducted; (b) the execution and delivery of this Agreement has been duly authorized and no ‘further approval, corporate or
otherwise, is required in order to execute this valid, binding and enforceable Agreement; (c) each individual listed as an inventor of the Ancestral Technology Patent Rights has assigned all of his or her rights, title and interests in and to
such Ancestral Technology Patent Rights to MEE pursuant to a binding written agreement between such inventor and MEE; (d) it is not a party to any agreement that is inconsistent or in conflict with the rights and licenses granted to TDTx
hereunder; (e) its execution, delivery and performance of this Agreement shall not conflict with the terms of any other agreement to which it is a party or by which it is bound; (f), no claims have been asserted or threatened against MEE in
writing (1) challenging the validity or ownership of the Licensed Intellectual Property, and/or (2) to the effect that the use, development or commercialization of Licensed Products using the Licensed Intellectual Property as contemplated
for TDTx under this Agreement infringes or will infringe or misappropriate any intellectual property right of any Third Party; and (g) the Ancestral Technology Patent Rights are not the subject of any litigation procedure, interference,
reissue, reexamination, opposition, appeal proceedings or any other formal legal proceeding. MEE shall not exercise any right it may have to terminate the Amended and Restated Lonza-MEE Agreement or to
otherwise materially amend or modify the Amended and Restated Lonza MEE Agreement in a way that materially adversely affects TDTx’s rights hereunder with respect to the Licensed Intellectual Property without the prior written consent of TDTx.

 ARTICLE 14 

NOTICES. 
 14.1
Notices to Lonza. Unless otherwise specified in this Agreement, reports, notices and other communications from TDTx or MEE to Lonza as provided hereunder must be sent to: 

Lonza Sales AG 
 Attn: Head of
Licensing 
 Muenchensteinerstrasse 38 CH-4402 

Basel, Switzerland 
 With a copy
to: 
 Assistant General Counsel 

Lonza America, Inc. 
 412 Mt
Kemble Ave. 
 Morristown, NJ 07960 

or other individuals or addresses as Lonza subsequently furnish by written notice to TDTx. 

14.2 Notices to MEE. Unless otherwise specified in this Agreement, reports, notices and other communications from Lonza or TDTx
to MEE as provided hereunder must be sent to: 
 Chief Innovation Officer, Innovation 

Massachusetts Eye and Ear Infirmary 

215 First Street, Suite 500 

Boston MA 02142 
 or other
individuals or addresses as MEE subsequently furnish by written notice to TDTx. 
 14.3 Notices to TDTx. Unless otherwise
specified in this Agreement, reports, notices and other communications from Lonza or MEE to TDTx as provided hereunder must be sent to: 

Chief Legal Officer 
 TDTx, Inc.

 One Broadway, 14`h Floor, Kendall Square 

Cambridge, MA 02142 
 or other
individuals or addresses as TDTx subsequently furnish by written notice to Licensors. 

  
 37. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 15 

DISPUTE RESOLUTION 

15.1 Negotiation between the Parties. The Parties shall first attempt to resolve any controversy or dispute that arises from or
under this Agreement, or any claim for a breach of the Agreement, by good faith negotiations during a [***] period for any payment based breach, and for a [***] period for any non-payment based breach, first
between their respective business development representatives. In the event that no agreement is reached with respect to such dispute during the applicable [***] or [***] period above after the commencement of such discussion, the matter shall be
referred to the Head of Licensing of Lonza, the President and CEO of MEE, and the CEO of TDTx (“Senior Executives”), who will discuss the matter in good faith and attempt to resolve it. 

15.2 Arbitration. Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or
validity thereof, that is not resolved within [***] after its referral to the Senior Executives pursuant to Section 16.1, but excluding any dispute, controversy or claim concerning the validity, enforceability, infringement or misappropriation
of any intellectual property, shall be finally settled by binding arbitration conducted in the English language in [***] by a panel of three (3) neutral arbitrators under the commercial arbitration rules of the American Arbitration Association,
which shall administer the arbitration and act as the appointing authorities. Disputes about arbitration procedure shall be resolved by the arbitrators. The three arbitrators shall be agreed upon by each of the Parties and shall not be current or
former employees, directors, or current stockholders, of any Party and shall be free of any conflict of interest or any appearance of conflict of or any appearance of conflict of interest with respect to any Party, or any of their respective
Affiliates, or Sublicensees. The arbitrators shall be authorized to grant interim relief, including to prevent the destruction of goods or documents involved in the dispute, protect trade secrets and provide for security for a prospective monetary
award. Within [***] after selection of the arbitrator, the arbitrator shall conduct the preliminary conference. In addressing any of the subjects within the scope of the preliminary conference, the arbitrator shall take into account both the
desirability of making discovery efficient and cost-effective and the needs of the Parties for an understanding of any legitimate issue raised in the arbitration. In addition, each Party shall have the right to take up to [***] of deposition
testimony, including expert deposition testimony. The hearing shall commence within [***] after the selection of the arbitrator. The arbitrator shall, in his or her discretion, allow each Party to submit concise written statements of position and
shall permit the submission of rebuttal statements, subject to reasonable limitations on the length of such statements to be established by the arbitrator. The hearing shall be no longer than [***] in duration. The arbitrator shall also permit the
submission of expert reports. The arbitrator shall render his or her decision and award within [***] after the arbitrator declares the hearing closed, and the decision and award shall include a written statement describing the essential findings and
conclusions on which the decision and award are based, including the calculation of any damages awarded. The arbitrator will, in rendering his or her decision, apply the substantive law of the [***], without reference to its conflict of laws
principles, and, with respect to disputes concerning rights in Intellectual Property, the laws of the United States of America. The arbitrator’s authority to award special, incidental, consequential or punitive damages shall be subject to the
limitation set forth in Section 12.3. The decision and award rendered by the arbitrator shall be final, binding and non-appealable, and judgment may be entered upon it in any court of competent
jurisdiction. Each Party shall bear its own attorney’s fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrator. 

15.3 Governing Law. The construction, validity and performance of the Agreement shall be governed by and construed in accordance
with the internal laws of the [***], without giving effect to its conflicts of laws provisions ([***]). 

  
 38. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 ARTICLE 16 

FORCE MAJEURE 
 Any delay
in the performance of any of the duties or obligations of any Party hereto (except the payment of money due hereunder) shall not be considered a breach of this Agreement, and the time required for performance shall be extended for a period equal to
the period of such delay, if such delay has been caused by or is the result of acts of God; acts of public enemy; insurrections; riots; injunctions; embargoes; labor disputes, including strikes, lockouts, job actions, or boycotts; fires; explosions;
earthquakes; floods; shortages of energy; governmental prohibition or restriction; or other unforeseeable causes beyond the reasonable control and without the negligence of the Party so affected. The Party so affected shall give prompt notice to the
other Parties of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. 

ARTICLE 17 

ASSIGNABILITY 
 This
Agreement shall be binding upon the successors and assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns. No Party may assign its interest under this Agreement without the
prior written consent of the other Parties, such consent not to be unreasonably withheld, conditioned or delayed; provided, however, that any Party shall be entitled, without the requirement to obtain any consent of the other Parties,
to assign this Agreement in its entirety to an Affiliate, or to the acquirer or transferee of all or substantially all of its business or assets pertaining to this Agreement, or to a successor or transferee of a controlling interest in the capital
stock of such Party, whether through purchase, merger, consolidation or other business combination, change of control or otherwise. Notwithstanding the preceding sentence, [***]. Any permitted assignment or transfer of this Agreement by any Party
will be conditioned upon that Party’s permitted assignee agreeing in writing to comply with all the terms and conditions contained in this Agreement and, in the case of assignment or transfer by Lonza or MEE, Lonza’s or MEE’s
permitted assignee assuming sole and exclusive Control of the Licensed Intellectual Property. Any purported assignment in violation of the foregoing will be void ab initio. No assignment shall relieve any Party of responsibility for the performance
of any obligations that accrued prior to the effective date of such assignment except to the extent they are performed by the relevant assignee in accordance with this Agreement. 

ARTICLE 18 

MISCELLANEOUS 
 18.1
MEE Policies. TDTx acknowledges that MEE’s employees and medical and professional staff members and the employees and staff members of MEE’s Affiliates are subject to the applicable policies of MEE and such Affiliates, including,
without limitation, policies regarding conflicts of interest, intellectual property and other matters. TDTx shall provide MEE with any agreement it proposes to enter into with any employee or staff member of MEE or any of MEE’s Affiliates for
MEE’s prior review and shall not enter into any oral or written agreement with such employee or staff member which conflicts with any such policy. MEE shall provide TDTx, at TDTx’s request, with copies of any such policies applicable to
any such employee or staff member. TDTx and MEE shall execute a side letter agreement in parallel with the execution of this Agreement, allowing MEE’s rights in any [***] under any consulting agreement(s) entered into between [***] and [***],
and any Patent Rights and Know-How directed thereto to be added, at no additional cost to TDTx, to the Licensed Intellectual Property exclusively licensed to TDTx under Section.2.1 of this Agreement. In
addition, to the extent that TDTx enters into any future [***], the Parties expect that TDTx and MEE will assess the situation in good faith, and, if appropriate under then-applicable MEE policies, enter into a side letter agreement similar to that
described above [***], and any Patent Rights and Know-How directed thereto to be added, at no additional cost to TDTx, to the Licensed Intellectual Property exclusively licensed to TDTx under Section 2.1
of this Agreement. 

  
 39. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 18.2 Relationship of Parties. Nothing in this Agreement is intended or shall
be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein.

 18.3 Further Actions. Each Party shall execute, acknowledge and deliver such further instruments, and do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 18.4 Use of Name;
Publicity. Neither Party shall use the name of any other Party (the non-disclosing Party) or of any trustee, director, officer, staff member, employee, student or agent of the non-disclosing Party, or any logo, trade name or trademark of the non-disclosing Party or any adaptation thereof in any advertising, promotional or sales literature, publicity
or in any document employed to obtain funds or financing without the prior written approval of the Party or individual whose name is to be used. For [***], such approval shall be obtained from [***]. Without the prior written consent as required
above of the non-disclosing Party, such consent not to be unreasonably withheld or delayed, no Party shall make any public announcement concerning this Agreement or the subject matter hereof; provided
however, that nothing in this Section 18.4 shall prevent any Party from the disclosure of any content which is not different from the content previously disclosed in any publicity or press release already approved by the Parties under
this Section 18.4, or from issuing statements that such Party determines to be necessary to comply with applicable law (including any stock exchange on which securities issued by such Party are traded), and provided further, that a Party
may refer to any existing publications in the scientific literature by a Party. 
 18.5 Waiver. A waiver by any Party of any
of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term of condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and
agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of any Party. 

18.6 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement. 
 18.7 Amendment. No amendment, modification or supplement of any provisions of this Agreement
shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
 18.8 Entire
Agreement. This Agreement together with the Stock Grant Agreement(s) and the Schedules hereto sets forth the entire agreement and understanding between Licensors and TDTx as to the subject matter hereof and supersedes any and all prior
discussions and negotiations between them, and no Party shall be bound by any conditions, definitions, warranties, understandings or representations with respect to such subject matter other than as expressly provided herein or as duly set forth on
or subsequent to the date hereof in writing and signed by a proper and duly authorized officer or representative of the Party to be bound thereby. 

18.9 Parties in Interest. All of the terms and provisions of this Agreement shall be binding upon, inure to the benefit of and
be enforceable by the Parties hereto and their respective permitted successors and assigns. 
 18.10 Descriptive Headings. The
descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. 

  
 40. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 18.11 Counterparts. This Agreement may be signed in counterparts, each and
every one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies of this Agreement from separate computers or printers.
Facsimile signatures shall be treated as original signatures. 
 18.12 No Presumption. The Parties agree that they have
participated equally in the formation of this Agreement and that the language herein should not be presumptively construed against either of them. 

18.13 Interpretation. The words “include,” “includes” and “including” shall be deemed to be
followed by the phrase “without limitation.” All references herein to Articles, Sections, and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall otherwise require.
Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or).
Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. Each Party represents that it has been represented by legal counsel or has voluntarily waived representation by legal counsel in
connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which
drafted such terms and provisions. Unless the context otherwise requires, countries shall include all territories and possessions. 
 * * *

  
 41. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date above.

  

			
	TDTx INC.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	CEO
	
	LONZA HOUSTON, INC.
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Global Head of Intellectual Property
	
	MASSACHUSETTS EYE AND EAR INFIRMARY
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Director, Licensing
	
	THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
		
	By:	 	 /s/ [***]

	Name:	 	[***]
	Title:	 	Managing Director, Licensing

  

SIGNATURE PAGE TO LICENSE AGREEMENT 

 Schedule A 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule B 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule C 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule D 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule E 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule F 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule G 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Schedule H 

[***] 

  
 . 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]